Egfr - epidermal growth factor receptor Gene
Also Known as Wa5; wa2; Erbb; Errp; wa-2; Errb1; 9030024J15Rik
Species: Mus musculus
About Egfr
This gene has 5 transcripts (splice variants), 283 orthologues, 53 paralogues and is associated with 180 phenotypes. Broad expression in liver adult (RPKM 26.7), liver E18 (RPKM 8.7) and 15 other tissues.
Summary
Enables epidermal growth factor binding activity and epidermal growth factor-activated receptor activity. Involved in cellular response to amino acid stimulus and positive regulation of fibroblast proliferation. Acts upstream of or within several processes, including animal organ development; epidermal growth factor receptor signaling pathway; and protein autophosphorylation. Located in several cellular components, including basolateral plasma membrane; endocytic vesicle; and perinuclear region of cytoplasm. Is expressed in several structures, including alimentary system; brain; integumental system; limb; and respiratory system. Used to study Coronavirus infectious disease and aortic valve disease. Human ortholog(s) of this gene implicated in several diseases, including colorectal cancer; lung non-small cell carcinoma (multiple); pancreatic cancer; prostate cancer; and pulmonary Tuberculosis. Orthologous to human EGFR (epidermal growth factor receptor). [provided by Alliance of Genome Resources, Apr 2022]
Egfr Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_207655.2 | NP_997538.1 | epidermal growth factor receptor isoform 1 precursor |
| NM_007912.4 | NP_031938.1 | epidermal growth factor receptor isoform 2 precursor |
Gene Ontology
- Molecular Function
- Biological Process
- Cellular Component
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| located in basolateral plasma membrane |
IDA
IDA: Inferred from direct assay
|
7723235 | MGI |
| located in cell surface |
IDA
IDA: Inferred from direct assay
|
23918928 | MGI |
| located in endocytic vesicle |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in intracellular anatomical structure |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in nucleus |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| located in perinuclear region of cytoplasm |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| is active in plasma membrane |
IDA
IDA: Inferred from direct assay
|
6248866 | MGI |
| located in plasma membrane |
IDA
IDA: Inferred from direct assay
|
7641815 | MGI |
| is active in plasma membrane |
IGI
IGI: Inferred from genetic interaction
|
28783046 | MGI |
Egfr Protein Structure
Recep_L_domain: pfam01030 (56 - 167)
Furin-like: pfam00757 (183 - 334)
Recep_L_domain: pfam01030 (361 - 480)
GF_recep_IV: pfam14843 (504 - 635)
TM_ErbB1: cd12093 (633 - 678)
PTKc_EGFR: cd05108 (705 - 1017)
- 0
- 200
- 400
- 600
- 800
- 1000
- 1210 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
epidermal growth factor receptor |
|
Recombinant Egfr Proteins
| Cat. No. | Product Name | Accession | Purity |
|---|---|---|---|
| HY-P72988 | EGFR Protein, Mouse (HEK293, Fc) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P72989 | EGFR Protein, Mouse (HEK293, His, solution) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-15772 | Osimertinib | Inhibitor | 99.96% | Yes |
| HY-P9907 | Trastuzumab | Inhibitor | 99.80% | Unkown |
| HY-P9905 | Cetuximab | Inhibitor | 99.81% | Unkown |
| HY-50895 | Gefitinib | Inhibitor | 99.99% | Yes |
| HY-138298A | Trastuzumab deruxtecan | Inhibitor | 99.89% | Unkown |
| HY-50896 | Erlotinib | Inhibitor | 99.99% | Yes |
| HY-10261 | Afatinib | Inhibitor | 99.92% | Yes |
| HY-138298 | Trastuzumab deruxtecan (solution) | Inhibitor | 99.40% | Unkown |
| HY-50898 | Lapatinib | Inhibitor | 99.83% | Yes |
| HY-16069 | Tucatinib | Inhibitor | 99.82% | Yes |
| HY-P9921 | Trastuzumab emtansine | Inhibitor | 99.74% | Unkown |
| HY-32721 | Neratinib | Inhibitor | 99.93% | Yes |
| HY-P9985 | Disitamab vedotin | Inhibitor | 99.06% | Unkown |
| HY-13272 | Dacomitinib | Inhibitor | 99.74% | Yes |
| HY-15772A | Osimertinib mesylate | Inhibitor | 99.97% | Yes |
| HY-109061 | Lazertinib | Inhibitor | 99.87% | Unkown |
| HY-P9921A | Trastuzumab emtansine (solution) | 98.27% | Unkown | |
| HY-12008 | Erlotinib Hydrochloride | Inhibitor | 99.94% | Yes |
| HY-10261A | Afatinib dimaleate | Inhibitor | 99.74% | Yes |
| HY-112870 | Firmonertinib | Inhibitor | 99.89% | Unkown |
| HY-112823 | Almonertinib | Inhibitor | 99.91% | Unkown |
| HY-104065 | Pyrotinib | Inhibitor | 98.84% | Unkown |
| HY-50895A | Gefitinib hydrochloride | Inhibitor | 99.85% | Yes |
| HY-132842 | Sunvozertinib | Inhibitor | 99.62% | Unkown |
| HY-N0281 | Daphnetin | Inhibitor | 99.77% | Unkown |
| HY-135815 | Mobocertinib | Inhibitor | 99.04% | Yes |
| HY-15164A | Icotinib | Inhibitor | 99.96% | Yes |
| HY-79077 | Osimertinib dimesylate | Inhibitor | 99.96% | Yes |
| HY-32721B | Neratinib maleate | Inhibitor | 99.74% | Yes |
| HY-164718 | Sevabertinib | Inhibitor | 99.90% | Unkown |
| HY-50898A | Lapatinib ditosylate | Inhibitor | 99.96% | Yes |
| HY-19730 | Olmutinib | Inhibitor | 99.88% | Unkown |
| HY-112870A | Firmonertinib mesylate | Inhibitor | 99.97% | Unkown |
| HY-15772R | Osimertinib (Standard) | Inhibitor | 99.69% | Unkown |
| HY-50898B | Lapatinib ditosylate monohydrate | Inhibitor | 99.99% | Yes |
| HY-104065B | Pyrotinib dimaleate | Inhibitor | 98.04% | Unkown |
| HY-112823A | Almonertinib mesylate | Inhibitor | 99.67% | Unkown |
| HY-112823B | Almonertinib hydrochloride | Inhibitor | 98.92% | Unkown |
| HY-135815A | Mobocertinib succinate | Inhibitor | 99.83% | Yes |
| HY-50896R | Erlotinib (Standard) | Inhibitor | 99.97% | Unkown |
| HY-16069A | Tucatinib hemiethanolate | Inhibitor | 98.82% | Yes |
| HY-15164 | Icotinib Hydrochloride | Inhibitor | 99.96% | Yes |
| HY-50895R | Gefitinib (Standard) | Inhibitor | 99.94% | Unkown |
| HY-118263 | Dacomitinib hydrate | Inhibitor | 99.54% | Unkown |
| HY-12008R | Erlotinib Hydrochloride (Standard) | Inhibitor | 99.73% | Unkown |
| HY-50898C | Lapatinib tosylate | Inhibitor | / | Unkown |
| HY-10261D | Afatinib oxalate | Inhibitor | / | Unkown |
| HY-135815B | Mobocertinib mesylate | Inhibitor | / | Unkown |
| HY-50895B | Gefitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-101820A | Simotinib hydrochloride | Inhibitor | / | Unkown |
| HY-12008A | Erlotinib mesylate | Inhibitor | / | Unkown |
| HY-50898BR | Lapatinib ditosylate monohydrate (Standard) | Inhibitor | 98.15% | Unkown |
| HY-15164AR | Icotinib (Standard) | Inhibitor | / | Unkown |
| HY-50895AR | Gefitinib hydrochloride (Standard) | Inhibitor | 99.46% | Unkown |
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9977 | Amivantamab | Inhibitor | 99.90% | Unkown |
| HY-P9912 | Pertuzumab | Inhibitor | 99.80% | Unkown |
| HY-P99041 | Panitumumab | Inhibitor | 99.77% | Unkown |
| HY-P99380 | Zanidatamab | Inhibitor | 98.56% | Unkown |
| HY-P99507 | Zenocutuzumab | Inhibitor | 99.9% | Unkown |
| HY-P9968 | Nimotuzumab | Inhibitor | 96.80% | Unkown |
| HY-P9964 | Necitumumab | Inhibitor | 99.82% | Unkown |
| HY-P99030 | Margetuximab | Inhibitor | ≥99.0% | Unkown |
Clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-14596 | Genistein | Inhibitor | 99.82% | Phase 4 |
| HY-137433 | Befotertinib | Inhibitor | 99.77% | Phase 4 |
| HY-131686 | Ganglioside GT1b (bovine) ammonium | Activator | 98.0% | Phase 4 |
| HY-50895G | Gefitinib (GMP) | Inhibitor | / | Phase 4 |
| HY-P99813 | Patritumab deruxtecan | 99.08% | Phase 3 | |
| HY-P99406 | Petosemtamab | Degrader | 99.90% | Phase 3 |
| HY-18750 | Zorifertinib | Inhibitor | 99.37% | Phase 3 |
| HY-171265 | Becotatug vedotin | Inhibitor | 96.99% | Phase 3 |
| HY-15729 | Rociletinib | Inhibitor | 99.67% | Phase 3 |
| HY-15730 | Poziotinib | Inhibitor | 99.96% | Phase 3 |
| HY-132259 | Depatuxizumab mafodotin | 99.65% | Phase 3 | |
| HY-12872 | Nazartinib | Inhibitor | 99.53% | Phase 3 |
| HY-164762 | Trastuzumab rezetecan | Inhibitor | 98.01% | Phase 3 |
| HY-112299 | Zipalertinib | Inhibitor | 99.62% | Phase 3 |
| HY-139920 | Oritinib | Inhibitor | 99.59% | Phase 3 |
| HY-19803 | Naquotinib mesylate | Inhibitor | 98.06% | Phase 3 |
| HY-19816A | Avitinib maleate | Inhibitor | 99.86% | Phase 3 |
| HY-13314 | Tesevatinib | Inhibitor | 99.41% | Phase 3 |
| HY-120590 | Ruserontinib | Inhibitor | 99.32% | Phase 3 |
| HY-P990697 | Anvatabart | Inhibitor | 98.15% | Phase 3 |
| HY-138751A | limertinib diTFA | Inhibitor | 98.96% | Phase 3 |
| HY-118998 | TX2-121-1 | Degrader | 98.01% | Phase 3 |
| HY-10530A | Varlitinib tosylate | Inhibitor | / | Phase 3 |
| HY-106204 | Nelipepimut-S | / | Phase 3 | |
| HY-N14349 | Asterriquinone | Inhibitor | / | Phase 3 |
| HY-109189A | Rezivertinib hydrochloride | Inhibitor | / | Phase 3 |
| HY-172820 | Trastuzumab envedotin | Inhibitor | / | Phase 3 |
| HY-13050 | Sapitinib | Inhibitor | 99.93% | Phase 2 |
| HY-10367 | Canertinib | Inhibitor | 99.74% | Phase 2 |
| HY-P99268 | Seribantumab | Inhibitor | 96.043% | Phase 2 |
| HY-32718 | Pelitinib | Inhibitor | 99.13% | Phase 2 |
| HY-153268 | Silevertinib | Inhibitor | 99.74% | Phase 2 |
| HY-10045 | AEE788 | Inhibitor | 98.39% | Phase 2 |
| HY-14674 | CP-724714 | Inhibitor | 98.72% | Phase 2 |
| HY-10333 | BMS-690514 | Inhibitor | 99.68% | Phase 2 |
| HY-19985 | PF-06459988 | Inhibitor | 99.10% | Phase 2 |
| HY-12972 | Mavelertinib | Inhibitor | 99.34% | Phase 2 |
| HY-172429A | Enozertinib hemihydrate | Inhibitor | 99.98% | Phase 2 |
| HY-17632 | Tarloxotinib bromide | Inhibitor | 98.75% | Phase 2 |
| HY-19815 | Olafertinib | Inhibitor | 99.51% | Phase 2 |
| HY-10251 | BMS-599626 | Inhibitor | 98.56% | Phase 2 |
| HY-107367A | Epertinib hydrochloride | Inhibitor | 98.15% | Phase 2 |
| HY-19909 | NRC-2694 | Antagonist | 99.84% | Phase 2 |
| HY-155537 | Pruvonertinib | Inhibitor | 99.50% | Phase 2 |
| HY-153974 | BBT-176 | Inhibitor | 98.98% | Phase 2 |
| HY-W423595 | BEBT-109 | Inhibitor | 98.72% | Phase 2 |
| HY-107367 | Epertinib | Inhibitor | ≥98.0% | Phase 2 |
| HY-P9994 | Pertuzumab zuvotolimod | Inhibitor | 98.64% | Phase 2 |
| HY-177414 | BB-1701 | Inhibitor | 98.81% | Phase 2 |
| HY-P991240 | CDX-3379 | Inhibitor | 99.38% | Phase 2 |
| HY-P991092 | IBI-334 | Inhibitor | 98.18% | Phase 2 |
| HY-101756 | SDZ281-977 | 98.00% | Phase 2 | |
| HY-164387A | Sutetinib maleate | Inhibitor | / | Phase 2 |
| HY-10223 | CUDC-101 | Inhibitor | 99.05% | Phase 1 |
| HY-13501 | Mubritinib | Inhibitor | 99.91% | Phase 1 |
| HY-164202 | ORM-5029 | Inhibitor | 96.53% | Phase 1 |
| HY-18957 | Lifirafenib | Inhibitor | 98.01% | Phase 1 |
| HY-144680 | BLU-945 | Inhibitor | 99.61% | Phase 1 |
| HY-14346 | PD153035 | Inhibitor | 98.56% | Phase 1 |
| HY-171124 | Tilatamig samrotecan | Inhibitor | 95.26% | Phase 1 |
| HY-136789 | Tuxobertinib | Inhibitor | 99.88% | Phase 1 |
| HY-15196 | TAK-285 | Inhibitor | 98.99% | Phase 1 |
| HY-103443 | HKI-357 | Inhibitor | 99.24% | Phase 1 |
| HY-B0794 | AZ7550 | Inhibitor | 97.09% | Phase 1 |
| HY-116437 | Selatinib | Inhibitor | 98.56% | Phase 1 |
| HY-155079 | DZD1516 | Inhibitor | 99.62% | Phase 1 |
| HY-10346 | AV-412 | Inhibitor | 99.17% | Phase 1 |
| HY-101820 | Simotinib | Inhibitor | 99.39% | Phase 1 |
| HY-P99685 | Laprituximab emtansine | Inhibitor | 97.66% | Phase 1 |
| HY-153110 | Larotinib | Inhibitor | 99.50% | Phase 1 |
| HY-139300 | Epitinib | Inhibitor | 99.95% | Phase 1 |
| HY-164694 | Emupertinib | Inhibitor | 99.10% | Phase 1 |
| HY-171747 | AMT-562 | Antagonist | 98.65% | Phase 1 |
| HY-177895 | IAM1363 | Inhibitor | 99.40% | Phase 1 |
| HY-111553 | TAS0728 | Inhibitor | 99.71% | Phase 1 |
| HY-128778 | Gozanertinib | Inhibitor | 98.30% | Phase 1 |
| HY-164307 | Pebezertinib | Inhibitor | 99.56% | Phase 1 |
| HY-164464 | BPI-15086 | Inhibitor | 99.08% | Phase 1 |
| HY-15732 | BGB-102 | Inhibitor | 99.52% | Phase 1 |
| HY-104066A | Theliatinib tartrate | / | Phase 1 | |
| HY-181954 | ZW-49 | Inhibitor | / | Phase 1 |
| HY-110039 | BIBX 1382 dihydrochloride | Inhibitor | / | Phase 1 |
| HY-153856 | TAS2940 | Inhibitor | / | Phase 1 |
| HY-110333 | BMS-599626 dihydrochloride | Inhibitor | / | Phase 1 |
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P99041A | Panitumumab (anti-EGFR) | Inhibitor | 99.02% | Phase 4 |
| HY-P99969 | Inetetamab | Inhibitor | 96.54% | Phase 4 |
| HY-P99854A | Disitamab (powder) | Inhibitor | 98.44% | Phase 4 |
| HY-P99041B | Panitumumab (powder) | Inhibitor | / | Phase 4 |
| HY-P99676 | Izalontamab | Inhibitor | 99.89% | Phase 3 |
| HY-P99849 | Depatuxizumab | Inhibitor | 99.58% | Phase 3 |
| HY-P99155 | Zalutumumab | 98.34% | Phase 3 | |
| HY-P990049 | Becotatug | Inhibitor | 99.00% | Phase 3 |
| HY-P99437 | Anbenitamab | Inhibitor | 99.22% | Phase 3 |
| HY-P99455 | Bafisontamab | Inhibitor | 99.9% | Phase 3 |
| HY-P99831 | Coprelotamab | / | Phase 3 | |
| HY-P991588 | HLX-22 | Antagonist | 99.47% | Phase 3 |
| HY-P991508 | Sym004 | Inhibitor | 98.97% | Phase 3 |
| HY-P99155A | Zalutumumab (powder) | Inhibitor | / | Phase 3 |
| HY-P9969 | Matuzumab | 99.50% | Phase 2 | |
| HY-P99936 | Elgemtumab | Inhibitor | 99.00% | Phase 2 |
| HY-P99778 | Ontuxizumab | 99.85% | Phase 2 | |
| HY-P990314 | AFM24 | Inhibitor | 96.26% | Phase 2 |
| HY-P99295 | Imgatuzumab | Inhibitor | 99.41% | Phase 2 |
| HY-P990071 | Fepixnebart | Inhibitor | 96.46% | Phase 2 |
| HY-P99605 | Cinrebafusp alfa | Inhibitor | 98.53% | Phase 2 |
| HY-P99306 | Modotuximab | Inhibitor | 99.08% | Phase 2 |
| HY-P99628 | Futuximab | Inhibitor | 98.09% | Phase 2 |
| HY-P991237 | Nezutatug | Inhibitor | 99.9% | Phase 2 |
| HY-P991571 | GC1118 | 99.22% | Phase 2 | |
| HY-P990913 | Dalmitamig | 97.158% | Phase 2 | |
| HY-P99672 | Istiratumab | Inhibitor | 98.45% | Phase 2 |
| HY-P991238 | MEDI4276 Antibody | Inhibitor | 96.5212% | Phase 2 |
| HY-P991507 | SCT200 | Inhibitor | 99.09% | Phase 2 |
| HY-P99500 | Cetuximab sarotalocan | Inhibitor | / | Phase 2 |
| HY-P991524 | MM-111 | Inhibitor | / | Phase 2 |
| HY-P991233 | BAT1006 | Inhibitor | / | Phase 2 |
| HY-P991572 | MM-151 | Antagonist | / | Phase 2 |
| HY-P99896 | Runimotamab | 99.00% | Phase 1 | |
| HY-P99386 | Vesencumab | Inhibitor | 99.34% | Phase 1 |
| HY-P99304 | Lumretuzumab | Inhibitor | ≥99.0% | Phase 1 |
| HY-P991235 | FS102 | Degrader | / | Phase 1 |
| HY-P991244 | REGN-1400 | Inhibitor | / | Phase 1 |
| HY-P991984 | SIBP-03 | Inhibitor | / | Phase 1 |
| HY-P990609 | KHK-2866 | 98.23% | Phase 1 |
Pre-clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-12000 | AG490 | Inhibitor | 99.86% | Unkown |
| HY-P0221 | PACAP (1-38), human, ovine, rat | Inducer | 99.99% | Unkown |
| HY-13524 | AG-1478 | Inhibitor | 99.57% | Unkown |
| HY-P99275 | Patritumab | Inhibitor | 99.28% | Unkown |
| HY-P10408 | Candidalysin | Activator | 99.81% | Unkown |
| HY-164702 | BL-B01D1 | Inhibitor | 98.59% | Unkown |
| HY-101084 | NSC 228155 | Activator | 99.58% | Unkown |
| HY-164992 | Trastuzumab vedotin | Inhibitor | 98.05% | Unkown |
| HY-13595 | Chrysophanol | Inhibitor | 99.73% | Unkown |
| HY-N0280 | Corosolic acid | 99.95% | Unkown | |
| HY-16558 | Butein | Inhibitor | 99.64% | Unkown |
| HY-N2409 | Delphinidin chloride | Inhibitor | 98.0% | Unkown |
| HY-171135 | Cetuximab MMAE | Inhibitor | 99.64% | Unkown |
| HY-100848 | TX1-85-1 | Inhibitor | 99.65% | Unkown |
| HY-12461 | WS6 | Activator | 99.30% | Unkown |
| HY-100958 | 4-DAMP | Inhibitor | 99.96% | Unkown |
| HY-B0793 | AZ-5104 | Inhibitor | 99.91% | Unkown |
| HY-156698 | HJM-561 | Degrader | 99.52% | Unkown |
| HY-N7922 | Urolithin M5 | 97.31% | Unkown | |
| HY-100742 | GNE-140 racemate | Inhibitor | 99.25% | Unkown |
| HY-123921 | Gefitinib-based PROTAC 3 | Degrader | 99.98% | Unkown |
| HY-19816 | Avitinib | Inhibitor | 99.95% | Unkown |
| HY-15644 | Tyrphostin 23 | Inhibitor | 98.19% | Unkown |
| HY-14596R | Genistein (Standard) | Inhibitor | 98.70% | Unkown |
| HY-168438 | ERBB agonist-1 | Agonist | 99.16% | Unkown |
| HY-108052 | Delphinidin 3-glucoside chloride | Inhibitor | 99.89% | Unkown |
| HY-N0447 | 8-Gingerol | Inhibitor | 99.72% | Unkown |
| HY-162713 | MTX-531 | Inhibitor | 99.87% | Unkown |
| HY-120852 | JG26 | Inhibitor | 98.14% | Unkown |
| HY-112411 | PD 174265 | Inhibitor | 98.35% | Unkown |
| HY-W016412 | Coenzyme Q0 | Inhibitor | 99.79% | Unkown |
| HY-129550 | BI-4020 | Inhibitor | 99.30% | Unkown |
| HY-13896 | PD168393 | Inhibitor | 98.01% | Unkown |
| HY-41404 | Piperonylic acid | 99.94% | Unkown | |
| HY-109189 | Rezivertinib | Inhibitor | 99.62% | Unkown |
| HY-48999A | FSK hydrochloride | 99.97% | Unkown | |
| HY-131864 | SJF-1528 | Degrader | 99.45% | Unkown |
| HY-100434 | PD-161570 | Inhibitor | 98.78% | Unkown |
| HY-141640 | MS154 | Inhibitor | 99.71% | Unkown |
| HY-138751 | limertinib | Inhibitor | 99.15% | Unkown |
| HY-N0211 | Cyasterone | Inhibitor | 99.58% | Unkown |
| HY-N2450 | Sulforaphene | Inhibitor | 99.78% | Unkown |
| HY-18609 | PD158780 | Inhibitor | 99.47% | Unkown |
| HY-155736 | MAPK-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-W782083 | p-SCN-Bn-NOTA trihydrochloride | 99.75% | Unkown | |
| HY-P990957 | Ficerafusp alfa | Substrate | 99.71% | Unkown |
| HY-125168 | EGA | Modulator | 99.76% | Unkown |
| HY-N2184 | Furanodienone | 99.90% | Unkown | |
| HY-14596S | Genistein-d4 | Inhibitor | 98.81% | Unkown |
| HY-10530 | Varlitinib | Inhibitor | 99.92% | Yes |
| HY-141676 | HyT36 | Degrader | 96.0% | Unkown |
| HY-N7005 | Clitorin | Inhibitor | 99.45% | Unkown |
| HY-15375 | Allitinib | Inhibitor | 98.88% | Unkown |
| HY-100213 | EAI045 | Inhibitor | 99.06% | Unkown |
| HY-N0891 | Tubeimoside II | Inhibitor | 99.90% | Unkown |
| HY-10322 | Falnidamol | Inhibitor | 98.36% | Unkown |
| HY-138916 | PF-06672131 | Inhibitor | 99.47% | Unkown |
| HY-10367A | Canertinib dihydrochloride | Inhibitor | 99.68% | Unkown |
| HY-157229 | STX-721 | Inhibitor | 98.43% | Unkown |
| HY-115605 | CN009543V | Agonist | 99.37% | Unkown |
| HY-20878 | Tyrphostin AG 879 | Inhibitor | 99.26% | Unkown |
| HY-156712 | Depatuxizumab MMAE | Inhibitor | 99.73% | Unkown |
| HY-N9330 | Broussoflavonol F | Inhibitor | 98.11% | Unkown |
| HY-B0794B | AZ7550 Mesylate | Inhibitor | 98.70% | Unkown |
| HY-10261B | (E/Z)-Afatinib | Inhibitor | 99.98% | Unkown |
| HY-18963 | Lavendustin A | Inhibitor | 99.09% | Unkown |
| HY-114243 | DpC | Modulator | 98.73% | Unkown |
| HY-131865 | SJF-1521 | Degrader | 99.65% | Unkown |
| HY-P99866 | Duligotuzumab | Inhibitor | 99.17% | Unkown |
| HY-N2524 | Camelliaside A | Ligand | 99.65% | Unkown |
| HY-123578 | NSC689857 | Inhibitor | 99.49% | Unkown |
| HY-N6942 | Mogroside IV-A | Inhibitor | 99.9% | Unkown |
| HY-161536 | PROTAC EGFR degrader 9 | Inhibitor | 98.35% | Unkown |
| HY-124813 | PDZ1i | Inhibitor | 99.29% | Unkown |
| HY-N2510 | Myristicin | Inhibitor | 99.89% | Unkown |
| HY-104066 | Theliatinib | Inhibitor | 99.72% | Unkown |
| HY-109061B | Lazertinib mesylate | Inhibitor | 99.85% | Unkown |
| HY-108484 | PP 3 | Inhibitor | 99.20% | Unkown |
| HY-108016 | Peruvoside | Inhibitor | 99.32% | Unkown |
| HY-10325 | CL-387785 | Inhibitor | 99.31% | Unkown |
| HY-157581 | MS39 | Degrader | 99.89% | Unkown |
| HY-134877 | BAY 2476568 | Inhibitor | 99.88% | Unkown |
| HY-12026 | WZ4002 | Inhibitor | 98.99% | Unkown |
| HY-112097 | E260 | Inhibitor | 99.92% | Unkown |
| HY-13464 | ALK-IN-1 | Inhibitor | 99.42% | Unkown |
| HY-137191 | CH7233163 | Inhibitor | 99.41% | Unkown |
| HY-147858 | PROTAC EGFR degrader 7 | Degrader | 99.85% | Unkown |
| HY-115481 | EphB1-IN-1 | Inhibitor | 99.51% | Unkown |
| HY-N2445 | Flavokawain C | Inhibitor | 99.79% | Unkown |
| HY-150611 | EGFR-IN-70 | Inhibitor | 98.12% | Unkown |
| HY-19729 | Naquotinib | Inhibitor | 98.10% | Unkown |
| HY-107364 | MTX-211 | Inhibitor | 99.81% | Unkown |
| HY-172429 | Enozertinib | Inhibitor | 98.86% | Unkown |
| HY-147219A | SIAIS164018 hydrochloride | Degrader | 98.06% | Unkown |
| HY-103442 | CGP52411 | Inhibitor | 99.82% | Unkown |
| HY-114858 | Epiblastin A | Inhibitor | 99.44% | Unkown |
| HY-N4201 | β-Hydroxyisovalerylshikonin | Inhibitor | 99.83% | Unkown |
| HY-15772S | Osimertinib-d6 | Inhibitor | 99.70% | Unkown |
| HY-128862 | TQB-3804 | Inhibitor | 99.76% | Unkown |
| HY-12013 | PD153035 Hydrochloride | Inhibitor | 99.48% | Unkown |
| HY-128576 | DS21360717 | 99.80% | Unkown | |
| HY-15844 | AG-825 | Inhibitor | 98.13% | Unkown |
| HY-P991748 | Anti-Human/Mouse Amphiregulin Antibody (AR37) | Inhibitor | 99.544% | Unkown |
| HY-W018800 | 4(3H)-Quinazolinone | Inhibitor | 99.89% | Unkown |
| HY-13895 | WHI-P154 | Inhibitor | 98.77% | Unkown |
| HY-B1394 | Khellin | Inhibitor | 99.66% | Unkown |
| HY-163094 | EGFR-IN-95 | Inhibitor | 98.76% | Unkown |
| HY-162299 | EGFR kinase inhibitor 3 | Inhibitor | 99.03% | Unkown |
| HY-17499 | EGFR-IN-12 | Inhibitor | 99.60% | Unkown |
| HY-12001 | WZ-3146 | Inhibitor | 99.28% | Unkown |
| HY-13897 | CNX-2006 | Inhibitor | 98.00% | Unkown |
| HY-161275 | BI-4732 | Inhibitor | 98.81% | Unkown |
| HY-111415 | EGFR-IN-5 | Inhibitor | 99.49% | Unkown |
| HY-12010 | BMS-599626 Hydrochloride | Inhibitor | 98.90% | Unkown |
| HY-147183B | JBJ-09-063 hydrochloride | Inhibitor | 99.37% | Unkown |
| HY-147941A | MS9427 TFA | Degrader | 98.38% | Unkown |
| HY-130616 | EGFR-IN-11 | Inhibitor | 98.76% | Unkown |
| HY-153796 | PROTAC Her3 Degrader-8 | Degrader | 99.60% | Unkown |
| HY-144304 | PROTAC EGFR degrader 2 | Inhibitor | 95.09% | Unkown |
| HY-161408 | GePhos1 | 98.88% | Unkown | |
| HY-172470 | DSPE-PEG2000-GE11 | 95.29% | Unkown | |
| HY-18603 | FIIN-3 | Inhibitor | 99.01% | Unkown |
| HY-147942 | MS9449 | Degrader | 98.95% | Unkown |
| HY-139617 | Sec61-IN-3 | Inhibitor | 99.33% | Unkown |
| HY-13427 | Allitinib tosylate | Inhibitor | 99.11% | Unkown |
| HY-136430 | JCN037 | Inhibitor | 99.09% | Unkown |
| HY-101960A | Tyrphostin A51 | Inhibitor | 99.76% | Unkown |
| HY-P2503 | EGFR Protein Tyrosine Kinase Substrate | 99.46% | Unkown | |
| HY-146349 | PROTAC EGFR degrader 4 | Degrader | 99.70% | Unkown |
| HY-161633 | PROTAC EGFR degrader 11 | Degrader | 99.20% | Unkown |
| HY-117155 | PKI-166 | Inhibitor | 98.92% | Unkown |
| HY-P4082 | ErbB-2-binding peptide-1 | Ligand | 99.52% | Unkown |
| HY-N1073 | Wighteone | Inhibitor | 98.71% | Unkown |
| HY-110406 | 13(S)-HPODE | Activator | 95.05% | Unkown |
| HY-P5314 | OK2 | Inhibitor | 99.13% | Unkown |
| HY-153901 | PROTAC EGFR degrader 8 | Degrader | 98.90% | Unkown |
| HY-149530 | EGFR-IN-86 | Inhibitor | 99.92% | Unkown |
| HY-N1988 | Cucurbitacin IIa | Inhibitor | 99.90% | Unkown |
| HY-43533 | Tarlox-TKI | Inhibitor | 98.79% | Unkown |
| HY-P990755 | Pamvatamig | 98.00% | Unkown | |
| HY-161537 | EGFR ligand-9 | Inhibitor | 98.80% | Unkown |
| HY-175252 | PROTAC EGFR degrader 14 | Degrader | 99.26% | Unkown |
| HY-163428 | Perzebertinib | Inhibitor | 99.85% | Unkown |
| HY-12029 | WZ8040 | Inhibitor | 98.29% | Unkown |
| HY-150023 | BI-1622 | Inhibitor | 98.02% | Unkown |
| HY-147183A | JBJ-09-063 TFA | Inhibitor | 99.64% | Unkown |
| HY-138627A | AST5902 trimesylate | Inhibitor | 98.19% | Unkown |
| HY-W013857 | Lavendustin C | Inhibitor | 98.17% | Unkown |
| HY-P99948 | Etevritamab | 97.00% | Unkown | |
| HY-161126 | EGFR-IN-98 | Inhibitor | 99.12% | Unkown |
| HY-177008 | PROTAC HER2 degrader-1 | Degrader | 98.0% | Unkown |
| HY-175839 | PROTAC EGFR degrader 15 | Degrader | 99.23% | Unkown |
| HY-123035 | Gamendazole | Inhibitor | 99.44% | Unkown |
| HY-103566 | LY456236 | Inhibitor | 99.57% | Unkown |
| HY-P1828A | EGFRvIII peptide (PEPvIII) TFA | 98.73% | Unkown | |
| HY-RS04209 | EGFR Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-112293 | GW2974 | 99.16% | Unkown | |
| HY-103440 | EGFR/ErbB-2/ErbB-4 inhibitor-3 | Inhibitor | 96.78% | Unkown |
| HY-101429 | RG13022 | Inhibitor | 96.74% | Unkown |
| HY-123952 | RTC-5 | Inhibitor | 99.37% | Unkown |
| HY-P11308 | Cys-GE11 | 98.03% | Unkown | |
| HY-124674A | CCT365623 hydrochloride | Inhibitor | 98.07% | Unkown |
| HY-19985A | (3S,4S)-PF-06459988 | 98.97% | Unkown | |
| HY-157579 | MS154N | 99.30% | Unkown | |
| HY-79511 | FAAH-IN-2 | Ligand | 99.12% | Unkown |
| HY-P10792 | HER2-targeted peptide H6F | 98.85% | Unkown | |
| HY-101219 | VEGFR-IN-1 | Inhibitor | 99.07% | Unkown |
| HY-15336 | AG 555 | Inhibitor | 98.0% | Unkown |
| HY-101041 | (E)-AG 556 | Inhibitor | 99.91% | Unkown |
| HY-126320 | EGFR-IN-8 | Inhibitor | 98.01% | Unkown |
| HY-164919 | Calotatug ginistinag | Inhibitor | 95.94% | Unkown |
| HY-15769 | WHI-P180 | Inhibitor | 99.84% | Unkown |
| HY-150024 | BI-4142 | Inhibitor | 98.02% | Unkown |
| HY-100214 | EAI001 | Inhibitor | 99.93% | Unkown |
| HY-142283AS | Dosimertinib mesylate | Inhibitor | 99.50% | Unkown |
| HY-107459 | (E/Z)-AG490 | Inhibitor | 99.71% | Unkown |
| HY-118532 | Tyrphostin AG30 | Inhibitor | 98.51% | Unkown |
| HY-N6932 | Voacamine | 99.64% | Unkown | |
| HY-101450 | PF-6274484 | Inhibitor | 98.76% | Unkown |
| HY-157480 | EGFR/AURKB-IN-1 | Inhibitor | 99.43% | Unkown |
| HY-N7424 | 4,7-Dihydroxycoumarin | Inhibitor | 98.25% | Unkown |
| HY-135805B | (Rac)-JBJ-04-125-02 acetate | 96.03% | Unkown | |
| HY-112474 | Tyrphostin AG 112 | Inhibitor | 98.31% | Unkown |
| HY-111138 | CZC-8004 | Inhibitor | 99.81% | Unkown |
| HY-172920 | Wnt/β-catenin-IN-6 | Inhibitor | 98.34% | Unkown |
| HY-131864A | SJF-1528 hemihydrate | Degrader | 98.90% | Unkown |
| HY-142512 | EGFR-IN-24 | Inhibitor | 98.71% | Unkown |
| HY-15729A | Rociletinib hydrobromide | Inhibitor | 98.04% | Yes |
| HY-P99618 | Fidasimtamab | Inhibitor | 95.00% | Unkown |
| HY-156284 | EGFR-IN-89 | Inhibitor | 98.75% | Unkown |
| HY-101042 | AG-494 | Inhibitor | 98.69% | Unkown |
| HY-P10224A | G7-18NATE TFA | 98.06% | Unkown | |
| HY-13984 | NT-1 | Inhibitor | 99.40% | Unkown |
| HY-12806 | AG1557 | Inhibitor | 99.54% | Unkown |
| HY-N6577 | Astragaloside VI | 99.95% | Unkown | |
| HY-112420 | EGFR/ErbB-2-IN-2 | Inhibitor | 99.45% | Unkown |
| HY-119944 | JND3229 | Inhibitor | 99.38% | Unkown |
| HY-P99630 | Gancotamab antibody | Inhibitor | ≥99.0% | Unkown |
| HY-153110A | Larotinib mesylate hydrate | Inhibitor | 98.66% | Unkown |
| HY-141481 | DP-C-4 | Inhibitor | 98.15% | Unkown |
| HY-143337 | EGFR-IN-47 | Inhibitor | 96.01% | Unkown |
| HY-112345 | PD-089828 | Inhibitor | 98.07% | Unkown |
| HY-172414 | Andamertinib | Inhibitor | 99.06% | Unkown |
| HY-145960A | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic | Agonist | 97.70% | Unkown |
| HY-RS04472 | ERBB4 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-149889 | EGFR-IN-78 | Inhibitor | 99.57% | Unkown |
| HY-161927 | EGFR-TK-IN-4 | Inhibitor | 99.90% | Unkown |
| HY-101522 | CHMFL-EGFR-202 | Inhibitor | 99.75% | Unkown |
| HY-P11078A | LARLLT TFA | 99.89% | Unkown | |
| HY-101006 | Methyl 2,5-dihydroxycinnamate | Inhibitor | 99.77% | Unkown |
| HY-162890 | EGFR-IN-122 | Inhibitor | 99.98% | Unkown |
| HY-P1855 | HER2/neu (654-662) GP2 | 98.26% | Unkown | |
| HY-156741A | EGFR-IN-87 hydrochloride | Inhibitor | 98.0% | Unkown |
| HY-50898S | Lapatinib-d4 | Inhibitor | 99.02% | Unkown |
| HY-103441 | JNJ28871063 hydrochloride | Inhibitor | 98.36% | Unkown |
| HY-RS04466 | ERBB2 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-15801 | HG-14-10-04 | Inhibitor | 98.53% | Unkown |
| HY-179572 | STA-013 | Inhibitor | 99.18% | Unkown |
| HY-P991662 | AMG-595 Antibody | 96.94% | Unkown | |
| HY-50896S | Erlotinib-d6 | Inhibitor | 99.84% | Unkown |
| HY-139997 | DDC-01-163 | Degrader | 99.05% | Unkown |
| HY-131686A | Ganglioside GT1b (porcine) ammonium | Activator | 98% | Unkown |
| HY-158149 | T-1-PMPA | Inhibitor | 99.70% | Unkown |
| HY-151159 | DHFR-IN-4 | Inhibitor | 99.19% | Unkown |
| HY-170820 | XYD049 | Inhibitor | 99.46% | Unkown |
| HY-133780 | Afatinib impurity 11 | Inhibitor | 99.10% | Unkown |
| HY-100064 | O-Desmethyl gefitinib | Inhibitor | 99.40% | Unkown |
| HY-164763 | SHR-A1201 | Inhibitor | 97.35% | Unkown |
| HY-101426 | RG14620 | Inhibitor | 99.02% | Unkown |
| HY-100923 | H-9 Dihydrochloride | Inhibitor | 98.98% | Unkown |
| HY-N1166 | Tephrosin | 98.02% | Unkown | |
| HY-161781 | HVH-2930 | Inhibitor | 96.54% | Unkown |
| HY-157582 | MS39N | Control | 98.0% | Unkown |
| HY-13450 | ZM 449829 | Inhibitor | 99.73% | Unkown |
| HY-113599 | Isoprocurcumenol | Activator | 95.41% | Unkown |
| HY-50895S2 | Gefitinib-d3 | Inhibitor | 98.39% | Unkown |
| HY-156872 | MTX-216 | Inhibitor | / | Unkown |
| HY-112870AS | Firmonertinib-d3 mesylate | 99.00% | Unkown | |
| HY-50895S | Gefitinib-d8 | Inhibitor | 98.42% | Unkown |
| HY-19617 | EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-100962 | (E)-AG 99 | Inhibitor | 98.12% | Unkown |
| HY-135805A | (Rac)-JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-131067 | EMI56 | Inhibitor | 99.36% | Unkown |
| HY-19617A | EGFR-IN-1 hydrochloride | Inhibitor | / | Unkown |
| HY-152852 | Mefatinib free base | Inhibitor | 99.40% | Unkown |
| HY-147941 | MS9427 | Degrader | 95.29% | Unkown |
| HY-147183 | JBJ-09-063 | Inhibitor | / | Unkown |
| HY-132842A | (S)-Sunvozertinib | Inhibitor | 99.05% | Unkown |
| HY-139300A | Epitinib succinate | Inhibitor | 99.01% | Unkown |
| HY-115716 | EGFR-IN-17 | Inhibitor | 98.18% | Unkown |
| HY-130608 | Mutated EGFR-IN-3 | Inhibitor | / | Unkown |
| HY-138627 | AST5902 | Inhibitor | / | Unkown |
| HY-P2673A | Lys-Arg-Thr-Leu-Arg-Arg acetate | / | Unkown | |
| HY-131088A | N3-PEG8-Phe-Lys-PABC-Gefitinib TFA | Inhibitor | / | Unkown |
| HY-108931 | AG 1406 | Inhibitor | 99.03% | Unkown |
| HY-136612 | DCBA | 98.92% | Unkown | |
| HY-170928 | DA-0157 | Inhibitor | 99.59% | Unkown |
| HY-149636 | Multi-target kinase inhibitor 2 | Inhibitor | 99.82% | Unkown |
| HY-150610 | EGFR-IN-69 | Inhibitor | 99.58% | Unkown |
| HY-10346A | AV-412 free base | Inhibitor | 98.10% | Unkown |
| HY-151048 | JBJ-07-149 | Inhibitor | 99.09% | Unkown |
| HY-144677 | pan-HER-IN-2 | Inhibitor | 98.10% | Unkown |
| HY-13272S2 | Dacomitinib-d10 dihydrochloride | Inhibitor | ≥95.0% | Unkown |
| HY-P2673 | Lys-Arg-Thr-Leu-Arg-Arg | / | Unkown | |
| HY-B0794A | AZ7550 hydrochloride | Inhibitor | 98.66% | Unkown |
| HY-P991149 | Nesfrotamig | Activator | 99.22% | Unkown |
| HY-U00002 | ZD-4190 | Inhibitor | 98.08% | Unkown |
| HY-153111 | EGFR/HER2-IN-9 | Inhibitor | 98.73% | Unkown |
| HY-158310 | SOS1/EGFR-IN-1 | Inhibitor | 99.54% | Unkown |
| HY-164387 | Sutetinib | Inhibitor | 99.27% | Unkown |
| HY-101007A | (+)-Tyrphostin B44 | Inhibitor | 99.10% | Unkown |
| HY-161618 | MJ04 | Inhibitor | 98.08% | Unkown |
| HY-19617B | EGFR-IN-1 TFA | Inhibitor | 99.38% | Unkown |
| HY-15772S3 | Asandeutertinib | Inhibitor | 99.75% | Unkown |
| HY-50895S1 | Gefitinib-d6 | Inhibitor | 98.2% | Unkown |
| HY-N6651 | Isocryptotanshinone | Inhibitor | ≥98.0% | Unkown |
| HY-138072 | EMI1 | Inhibitor | 99.45% | Unkown |
| HY-103439 | GW583340 dihydrochloride | Inhibitor | / | Unkown |
| HY-12872B | Nazartinib S-enantiomer | 95.10% | Unkown | |
| HY-155005 | EGFR mutant-IN-2 | Inhibitor | 97.0% | Unkown |
| HY-126850 | 4-Epidoxycycline | / | Unkown | |
| HY-131088 | N3-PEG8-Phe-Lys-PABC-Gefitinib | Inhibitor | / | Unkown |
| HY-183682 | AZ14289671 | Inhibitor | 99.77% | Unkown |
| HY-183068 | AP4-43 | Inhibitor | 99.76% | Unkown |
| HY-155358 | Os30 | Inhibitor | 98.34% | Unkown |
| HY-156741 | EGFR-IN-87 | Inhibitor | / | Unkown |
| HY-101958 | Tyrphostin 25 | Inhibitor | 99.00% | Unkown |
| HY-155285 | YS-363 | Inhibitor | 99.52% | Unkown |
| HY-147858A | PROTAC EGFR degrader 7 diTFA | Degrader | 97.15% | Unkown |
| HY-P992128 | Rinumafusp alfa | Inhibitor | 97.09% | Unkown |
| HY-126319 | SU5204 | Inhibitor | 99.46% | Unkown |
| HY-108486 | Herbimycin A | Degrader | 99% | Unkown |
| HY-162254 | EGFR/ACK1-IN-1 | Inhibitor | 98.19% | Unkown |
| HY-111452 | EGFR-IN-85 | Inhibitor | / | Unkown |
| HY-P3744 | pp60v-src Autophosphorylation site | 99.93% | Unkown | |
| HY-145960 | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 | Agonist | 99.39% | Unkown |
| HY-129510 | 4-Methyl erlotinib | Inhibitor | 99.34% | Unkown |
| HY-156912 | Tyrosine kinase-IN-7 | Inhibitor | 99.25% | Unkown |
| HY-147219 | SIAIS164018 | Degrader | / | Unkown |
| HY-135805 | JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-157413 | YS-67 | Inhibitor | 99.41% | Unkown |
| HY-10261S | Afatinib-d6 | Inhibitor | 99.0% | Unkown |
| HY-N10103 | Neoschaftoside | Modulator | 98.04% | Unkown |
| HY-14347 | EBE-A22 | Control | 99.86% | Unkown |
| HY-P990695 | Lunaxafusp (His Tag) | Inhibitor | / | Unkown |
| HY-15772S1 | Osimertinib-13C,d3 | 99.14% | Unkown | |
| HY-12008S | Erlotinib-d6 hydrochloride | Inhibitor | 98.13% | Unkown |
| HY-100499 | Tyrphostin AG 528 | Inhibitor | 98.0% | Unkown |
| HY-P992138 | Vadalentamig | Inhibitor | 96.79% | Unkown |
| HY-W001520 | 1-Methyl-1H-pyrrolo[2,3-b]pyridine | / | Unkown | |
| HY-21291 | SU-4313 | Modulator | 99.31% | Unkown |
| HY-B0794S | AZ7550-d5 | Inhibitor | / | Unkown |
| HY-164476 | ES-072 | Inhibitor | 98.05% | Unkown |
| HY-P992130 | Rolditamig | Inhibitor | 95.26% | Unkown |
| HY-123766 | EGFR-IN-99 | Inhibitor | 98.09% | Unkown |
| HY-P990698 | Umizortamig | 96.90% | Unkown | |
| HY-W109039 | EGFR ligand-15 | 97.03% | Unkown | |
| HY-12872A | Nazartinib mesylate | Inhibitor | / | Unkown |
| HY-188282 | Trastuzumab botidotin | / | Unkown | |
| HY-185832 | SYS6010 | Inhibitor | 98.19% | Unkown |
| HY-185816 | TQB2102 | Inhibitor | / | Unkown |
| HY-19981B | Derazantinib dihydrochloride | Inhibitor | / | Unkown |
| HY-100520 | EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-142283 | Dosimertinib | Inhibitor | / | Unkown |
| HY-18750A | Zorifertinib hydrochloride | Inhibitor | / | Unkown |
| HY-135914 | JBJ-02-112-05 | Inhibitor | / | Unkown |
| HY-189685 | BPI-361175 | Inhibitor | / | Unkown |
| HY-125841 | EGFR mutant-IN-1 | Inhibitor | / | Unkown |
| HY-189681 | QLH-11811 | Inhibitor | / | Unkown |
| HY-138298C | Trastuzumab deruxtecan (DAR4) | Inhibitor | / | Unkown |
| HY-B0793S1 | AZ-5104-d2 | Inhibitor | / | Unkown |
| HY-132883 | EGFR/CSC-IN-1 | Inhibitor | / | Unkown |
| HY-163354 | EGFR-IN-103 | Inhibitor | / | Unkown |
| HY-139920A | Oritinib mesylate | Inhibitor | / | Unkown |
| HY-128860 | Mutated EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-143734 | HER2-IN-6 | / | Unkown | |
| HY-168968S | ZJY-54 | Inhibitor | / | Unkown |
| HY-144048 | EGFR-IN-31 | / | Unkown | |
| HY-189682 | HS-10375 | Inhibitor | / | Unkown |
| HY-112806 | ST8155AA1 | / | Unkown | |
| HY-147303 | Sacibertinib | Inhibitor | / | Unkown |
| HY-114243A | DpC hydrochloride | Modulator | / | Unkown |
| HY-123726 | ErbB-1/ErbB-2 tyrosine kinase-IN-1 | / | Unkown | |
| HY-147407 | Imbotolimod | Inhibitor | / | Unkown |
| HY-115951 | EGFR/HER2-IN-2 | Inhibitor | / | Unkown |
| HY-152852A | Mefatinib | Inhibitor | 99.44% | Unkown |
| HY-131066 | EMI48 | Inhibitor | 99.45% | Unkown |
| HY-10407G | SU 5402 (GMP) | Inhibitor | / | Unkown |
| HY-137433A | Befotertinib mesylate | Inhibitor | / | Unkown |
| HY-13050A | Sapitinib fumarate | Inhibitor | / | Unkown |
| HY-142681 | EGFR-IN-28 | Inhibitor | / | Unkown |
| HY-161891 | EGFR/Akt-IN-1 | Inhibitor | / | Unkown |
| HY-190866 | EGFR/VEGFR-2/COX-2-IN-1 | Inhibitor | / | Unkown |
| HY-173492 | EGFR-IN-156 | Inhibitor | / | Unkown |
| HY-181775 | VEGFR-2/c-Met/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-163723 | EGFR-IN-116 | Inhibitor | / | Unkown |
| HY-138627AR | AST5902 trimesylate (Standard) | Inhibitor | / | Unkown |
| HY-10261AS | Afatinib-d6 dimaleate | Inhibitor | / | Unkown |
| HY-142283CS | N-Methyl-dosimertinib | / | Unkown | |
| HY-146472 | EGFR-IN-52 | Inhibitor | / | Unkown |
| HY-17654 | BIEGi-1 | Inhibitor | / | Unkown |
| HY-P5258 | Oligopeptide-41 | Inducer | 98.05% | Unkown |
| HY-175011 | EGFR-IN-165 | Inhibitor | / | Unkown |
| HY-161602 | EGFR/HER2-IN-13 | Inhibitor | / | Unkown |
| HY-180196 | EGFR-IN-187 | Inhibitor | / | Unkown |
| HY-15268 | PP487 | Inhibitor | / | Unkown |
| HY-164490 | LS-106 | Inhibitor | / | Unkown |
| HY-174232 | EGFR/CA-IX-IN-1 | Inhibitor | / | Unkown |
| HY-146170 | Anticancer agent 69 | Inhibitor | / | Unkown |
| HY-N1988R | Cucurbitacin IIa (Standard) | Inhibitor | / | Unkown |
| HY-162360 | EGFR-IN-109 | Inhibitor | / | Unkown |
| HY-172966 | EG31 | Inhibitor | / | Unkown |
| HY-143733 | HER2-IN-5 | Inhibitor | / | Unkown |
| HY-118900 | CP-654577 | Inhibitor | / | Unkown |
| HY-137028 | 2′-Thioadenosine | Inhibitor | / | Unkown |
| HY-150782 | UNC-CA359 | Inhibitor | / | Unkown |
| HY-176788 | EGFR Ligand-Linker Conjugates 1 | Inhibitor | / | Unkown |
| HY-134468 | PP124 | Inhibitor | / | Unkown |
| HY-168577 | KRAS G12D inhibitor 25 | Degrader | / | Unkown |
| HY-P5742A | ELAAWCRWGFLLALLPPGIAG TFA | / | Unkown | |
| HY-143901 | EGFR-IN-40 | Inhibitor | / | Unkown |
| HY-170559 | EGFR-IN-141 | Inhibitor | / | Unkown |
| HY-190462 | EGFPAN_EMBS | Inhibitor | / | Unkown |
| HY-157324 | EGFR-IN-94 | Inhibitor | / | Unkown |
| HY-178157 | Multi-target kinase-IN-7 | Inhibitor | / | Unkown |
| HY-146471 | EGFR-IN-51 | Inhibitor | / | Unkown |
| HY-161923 | EGFR-IN-120 | Inhibitor | / | Unkown |
| HY-P11761 | HYNIC-H10F | Ligand | / | Unkown |
| HY-171252 | EGFR-IN-145 | Inhibitor | / | Unkown |
| HY-P9907S | 15N-Labeled Trastuzumab | / | Unkown | |
| HY-173164 | EGFR/BRAFV600E-IN-4 | Inhibitor | / | Unkown |
| HY-W714853 | (+)-Theta-cypermethrin | Ligand | / | Unkown |
| HY-151154 | EGFR/HER2/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-152852S | Mefatinib-d6 free base | Inhibitor | / | Unkown |
| HY-163420 | HER2-IN-16 | Inhibitor | / | Unkown |
| HY-172110 | Apoptosis inducer 35 | Inhibitor | / | Unkown |
| HY-182031 | JS04 | Inhibitor | / | Unkown |
| HY-182264 | Masoprocol tetrapivalate | Inhibitor | / | Unkown |
| HY-127067 | Yuanhuadin | Inhibitor | / | Unkown |
| HY-147802 | EGFR-IN-59 | Inhibitor | / | Unkown |
| HY-10261E | (R)-Afatinib | Inhibitor | / | Unkown |
| HY-146473 | EGFR-IN-53 | Inhibitor | / | Unkown |
| HY-149275 | PKM2/PDK1-IN-1 | Inhibitor | / | Unkown |
| HY-175805 | EGFR/HDAC-IN-2 | Inhibitor | / | Unkown |
| HY-175171 | Anticancer agent 276 | Inhibitor | / | Unkown |
| HY-12008S1 | Erlotinib-13C6 hydrochloride | Inhibitor | / | Unkown |
| HY-149632 | EGFR/HER2/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-156457 | EGFR-IN-90 | Inhibitor | / | Unkown |
| HY-168492 | TrxR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-175220 | 4-TCPA | Inhibitor | / | Unkown |
| HY-160682 | EGFR/HER2-IN-12 | Inhibitor | / | Unkown |
| HY-190642 | CDK2/TrkA-IN-1 | Inhibitor | / | Unkown |
| HY-182005 | EGFR/VEGFR2-IN-12 | Inhibitor | / | Unkown |
| HY-190912 | PKMYT1-IN-18 | Inhibitor | / | Unkown |
| HY-172534 | BPN-01 | Substrate | / | Unkown |
| HY-138746 | EGFR-IN-15 | Inhibitor | 96.21% | Unkown |
| HY-184311 | EGFR-IN-214 | Inhibitor | / | Unkown |
| HY-142679 | EGFR-IN-22 | Inhibitor | / | Unkown |
| HY-402309 | IGF-1R modulator 1 | Modulator | 99.75% | Unkown |
| HY-103630 | PROTAC Her3 Degrader-2 | Degrader | / | Unkown |
| HY-179522 | EGFR-IN-186 | Inhibitor | / | Unkown |
| HY-151882 | EGFR-IN-73 | Inhibitor | / | Unkown |
| HY-181714 | EGFR-IN-203 | Inhibitor | / | Unkown |
| HY-172780 | EGFR-IN-161 | Inhibitor | / | Unkown |
| HY-172897 | EGFR/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-160564 | ZNL-0056 | Inhibitor | / | Unkown |
| HY-147997 | EGFR-IN-68 | Inhibitor | / | Unkown |
| HY-P11944 | Peptide 22 | Chemical | / | Unkown |
| HY-171884 | BI-8128 | Inhibitor | / | Unkown |
| HY-146422 | PROTAC EGFR degrader 5 | Degrader | / | Unkown |
| HY-P11760 | HER2-targeted peptide H10 | Ligand | / | Unkown |
| HY-190668 | Antitumor agent-234 | Inhibitor | / | Unkown |
| HY-158175 | EGFR T790M/L858R-IN-4 | Inhibitor | / | Unkown |
| HY-163434 | PRMT5/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-13314A | Tesevatinib tosylate | Inhibitor | / | Unkown |
| HY-182742 | EGFR-IN-208 | Inhibitor | / | Unkown |
| HY-N6678S | (Rac)-Zearalanone-d6 | Degrader | / | Unkown |
| HY-183120 | EGFR T790M/FAK-IN-2 | Inhibitor | / | Unkown |
| HY-146228 | HSP90-IN-13 | Inhibitor | / | Unkown |
| HY-157526 | EGFR-TK-IN-1 | Inhibitor | / | Unkown |
| HY-178955 | EGFR-IN-182 | Inhibitor | / | Unkown |
| HY-179098 | Multi-target kinase-IN-8 | Inhibitor | / | Unkown |
| HY-146782 | EGFR-IN-49 | Inhibitor | / | Unkown |
| HY-170787 | TZEP7 | Inhibitor | / | Unkown |
| HY-180242 | EGFR/CDK2-IN-5 | Inhibitor | / | Unkown |
| HY-168627 | EGFR-IN-135 | Inhibitor | / | Unkown |
| HY-178442 | EGFR-IN-179 | Inhibitor | / | Unkown |
| HY-183310 | EGFR-IN-210 | Inhibitor | / | Unkown |
| HY-169346 | Pred17 | Inhibitor | / | Unkown |
| HY-P0221A | PACAP (1-38), human, ovine, rat TFA | Inducer | / | Unkown |
| HY-183253 | DL149 | Ligand | / | Unkown |
| HY-172877 | EGFR/BRAFV600E-IN-5 | Inhibitor | / | Unkown |
| HY-157398 | EGFR T790M/L858R-IN-3 | Inhibitor | / | Unkown |
| HY-P1828 | EGFRvIII peptide (PEPvIII) | / | Unkown | |
| HY-147796 | EGFR/HER2/CDK9-IN-1 | Inhibitor | / | Unkown |
| HY-149633 | EGFR/HER2/DHFR-IN-3 | Inhibitor | / | Unkown |
| HY-145824 | EGFR-IN-43 | Inhibitor | / | Unkown |
| HY-175297 | EGFR T790M/VEGFR-2-IN-1 | Inhibitor | / | Unkown |
| HY-146210 | EGFR-IN-50 | Inhibitor | / | Unkown |
| HY-146136 | EGFR-IN-56 | Inhibitor | / | Unkown |
| HY-179529 | EGFR/InhA-IN-1 | Inhibitor | / | Unkown |
| HY-178939 | EGFR-IN-181 | Inhibitor | / | Unkown |
| HY-144445 | NSC114126 | Inhibitor | / | Unkown |
| HY-104080 | HG-5-88-01 | Inhibitor | / | Unkown |
| HY-50898S5 | Lapatinib-13C,d7 | Inhibitor | / | Unkown |
| HY-P9905S | 15N-Labeled Cetuximab | / | Unkown | |
| HY-177710 | MEDI4276 | / | Unkown | |
| HY-164056 | EGFR T790M/L858R-IN-8 | Inhibitor | 99.20% | Unkown |
| HY-101960 | (Z)-Tyrphostin A51 | Inhibitor | / | Unkown |
| HY-173314 | EGFR-IN-155 | Inhibitor | / | Unkown |
| HY-169428 | EGFR-IN-138 | / | Unkown | |
| HY-15772G | Osimertinib (GMP) | Inhibitor | / | Unkown |
| HY-178440 | EGFR/COX-2-IN-2 | Inhibitor | / | Unkown |
| HY-112334 | EGFR-IN-198 | Inhibitor | 99.57% | Unkown |
| HY-181099 | EGFR WT/T790M-IN-4 | Inhibitor | / | Unkown |
| HY-170665 | EGFR T790M/L858R-IN-9 | Inhibitor | / | Unkown |
| HY-189915 | PROTAC EGFR degrader 20 | Degrader | / | Unkown |
| HY-155079A | (R)-DZD1516 | Control | 98.80% | Unkown |
| HY-175635 | EGFR/VEGFR2-IN-6 | Inhibitor | / | Unkown |
| HY-164489 | KU004 | Inhibitor | / | Unkown |
| HY-172470A | DSPE-PEG3400-GE11 | / | Unkown | |
| HY-161030 | EGFR-IN-92 | Inhibitor | / | Unkown |
| HY-170968 | EGFR-IN-150 | Inhibitor | / | Unkown |
| HY-161045 | T-1-DOCA | Inhibitor | / | Unkown |
| HY-RS04470 | Erbb3 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-150781 | EGFR-IN-71 | Inhibitor | / | Unkown |
| HY-179031 | EGFR/VEGFR2-IN-7 | Inhibitor | / | Unkown |
| HY-120857 | BPIQ-II hydrochloride | Inhibitor | / | Unkown |
| HY-P990049A | Becotatug (powder) | Inhibitor | / | Unkown |
| HY-175837 | EGFR-IN-172 | Inhibitor | / | Unkown |
| HY-178119 | HER4/HER2-IN-1 | Inhibitor | / | Unkown |
| HY-163453 | HER2-IN-19 | Inhibitor | / | Unkown |
| HY-189075 | I-0436650 | Inhibitor | / | Unkown |
| HY-146238 | EGFR/HER2/TS-IN-1 | Inhibitor | / | Unkown |
| HY-B0793GL | AZ-5104 (GMP Like) | Inhibitor | / | Unkown |
| HY-149407 | Multi-kinase-IN-4 | Inhibitor | / | Unkown |
| HY-163006 | EGFR/c-Met-IN-1 | Inhibitor | / | Unkown |
| HY-183311 | EGFR-IN-211 | Inhibitor | / | Unkown |
| HY-146132 | EGFR-IN-55 | Inhibitor | / | Unkown |
| HY-169309 | EGFR-IN-133 | Inhibitor | / | Unkown |
| HY-172471 | DSPE-PEG5000-GE11 | / | Unkown | |
| HY-P11613 | DOTA-WC8 | Ligand | / | Unkown |
| HY-173038 | EGFR-IN-151 | Inhibitor | / | Unkown |
| HY-146239 | EGFR/HER2/TS-IN-2 | Inhibitor | / | Unkown |
| HY-151049 | EGFR ligand-8 | Ligand | / | Unkown |
| HY-P10569 | Biotin HER-2 substrate peptide | / | Unkown | |
| HY-P10686 | CH401 peptide | / | Unkown | |
| HY-181776 | c-Met-IN-31 | Inhibitor | / | Unkown |
| HY-116059 | EGFR-IN-199 | Inhibitor | / | Unkown |
| HY-144052 | EGFR-IN-35 | Inhibitor | / | Unkown |
| HY-147992 | EGFR/HER2-IN-4 | Inhibitor | / | Unkown |
| HY-P11752 | Cyclo(KLARLLT) | Ligand | / | Unkown |
| HY-183277 | EGFR-IN-209 | Inhibitor | / | Unkown |
| HY-163402 | EGFR-IN-108 chloride | Inhibitor | / | Unkown |
| HY-163377 | AZ5385 | Inhibitor | / | Unkown |
| HY-181502 | EGFR-IN-197 | Inhibitor | / | Unkown |
| HY-185833 | ADC Control Human IgG1-JSSW-001 | Inhibitor | / | Unkown |
| HY-P992576 | Anti-EGFR Antibody (425) | Inhibitor | / | Unkown |
| HY-189146 | HDTAC EGFR Degrader-1 | Degrader | / | Unkown |
| HY-172623 | EGFR/HER2-IN-17 | Inhibitor | / | Unkown |
| HY-163418 | HER2-IN-17 | Inhibitor | / | Unkown |
| HY-181701 | EGFR-IN-202 | Inhibitor | / | Unkown |
| HY-147825 | EGFR/BRAFV600E-IN-1 | Inhibitor | / | Unkown |
| HY-50898CS | Lapatinib-d4 tosylate | Inhibitor | / | Unkown |
| HY-131710 | PDE5-IN-3 | Inhibitor | / | Unkown |
| HY-161031 | EGFR-IN-93 | Inhibitor | / | Unkown |
| HY-103629 | PROTAC Her3 Degrader-1 | Inhibitor | / | Unkown |
| HY-100064S | O-Desmethyl gefitinib-d8 | Inhibitor | 99.84% | Unkown |
| HY-178824 | EGFR-IN-180 | Inhibitor | / | Unkown |
| HY-146474 | EGFR-IN-54 | Inhibitor | / | Unkown |
| HY-10368 | EGFR/VEGFR2-IN-4 | Inhibitor | / | Unkown |
| HY-178448 | EGFR-IN-178 | Inhibitor | / | Unkown |
| HY-179600 | Dyrk1A-IN-16 | Inhibitor | / | Unkown |
| HY-181657 | EGFR-IN-200 | Inhibitor | / | Unkown |
| HY-180922 | EGFR kinase-IN-8 | Inhibitor | / | Unkown |
| HY-18957A | rel-Lifirafenib | Control | / | Unkown |
| HY-P5742 | ELAAWCRWGFLLALLPPGIAG | / | Unkown | |
| HY-129288 | GW837016X | Inhibitor | / | Unkown |
| HY-103439A | GW583340 | Inhibitor | / | Unkown |
| HY-161067 | EGFR-IN-96 | Inhibitor | / | Unkown |
| HY-18298 | PD 173955 analog 1 | Inhibitor | / | Unkown |
| HY-161136 | EGFR/STAT3-IN-1 | Inhibitor | / | Unkown |
| HY-189466 | EGFR-IN-219 | Inhibitor | / | Unkown |
| HY-B0793G | AZ-5104 (GMP) | Inhibitor | / | Unkown |
| HY-172104 | EGFR-IN-143 | Inhibitor | / | Unkown |
| HY-P10224 | G7-18NATE | / | Unkown | |
| HY-182064 | EGFR-IN-206 | Inhibitor | / | Unkown |
| HY-176938A | iAfaPhos1 | 98.27% | Unkown | |
| HY-187838S | Adonertinib | Inhibitor | / | Unkown |
| HY-168151 | EGFR-IN-128 | Inhibitor | / | Unkown |
| HY-170497 | EGFR-IN-140 | Inhibitor | / | Unkown |
| HY-115933 | EGFR/BRAF-IN-1 | Inhibitor | / | Unkown |
| HY-N16557 | (Rac)-8-Gingerol | Inhibitor | / | Unkown |
| HY-109061A | Lazertinib mesylate hydrate | Inhibitor | / | Unkown |
| HY-110328 | PKI-166 hydrochloride | Inhibitor | / | Unkown |
| HY-177009 | Tucatinib analog B | Ligand | / | Unkown |
| HY-161968 | EGFR/PI3Kα-IN-1 | Inhibitor | / | Unkown |
| HY-160613 | EGFR/HER2-IN-11 | Inhibitor | / | Unkown |
| HY-181166 | EGFR-IN-194 | Inhibitor | / | Unkown |
| HY-184301 | EGFR/HER2-IN-20 | Inhibitor | / | Unkown |
| HY-158177 | EGFR T790M/L858R-IN-6 | Inhibitor | / | Unkown |
| HY-144441 | NSC81111 | Inhibitor | / | Unkown |
| HY-143445 | EGFR-IN-48 | Inhibitor | / | Unkown |
| HY-175316 | EGFR-IN-168 | Inhibitor | / | Unkown |
| HY-181251 | EGFR-IN-195 | Inhibitor | / | Unkown |
| HY-185780 | Trastuzumab-DM21 | Inhibitor | / | Unkown |
| HY-163726 | GLUT1/EGFR-IN-1 | Inhibitor | 99.75% | Unkown |
| HY-13595R | Chrysophanol (Standard) | Inhibitor | / | Unkown |
| HY-175257 | Theophylline-platinum(IV) prodrug-1 | Inhibitor | / | Unkown |
| HY-150905 | EGFR ligand-2 | Inhibitor | / | Unkown |
| HY-161632 | PROTAC EGFR degrader 10 | Degrader | / | Unkown |
| HY-149824 | EGFR T790M/L858R-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-P10659 | Self-assembling peptide pY1 | / | Unkown | |
| HY-10188 | SKS-927 | Inhibitor | / | Unkown |
| HY-189638 | Antiproliferative agent-84 | Inhibitor | / | Unkown |
| HY-156033 | EGFR-IN-88 | Inhibitor | / | Unkown |
| HY-164988 | TX2-120-1 | Degrader | / | Unkown |
| HY-164392 | TAS-121 | Inhibitor | / | Unkown |
| HY-115952 | EGFR/HER2-IN-3 | Inhibitor | / | Unkown |
| HY-175809 | SRT6 | Inhibitor | 99.90% | Unkown |
| HY-138627B | AST5902 mesylate | Inhibitor | / | Unkown |
| HY-189760 | S-023-0996 | Inhibitor | / | Unkown |
| HY-P10995 | TAT-327 | Inhibitor | / | Unkown |
| HY-162332 | EGFR-PK/JNK-2-IN-1 | Inhibitor | / | Unkown |
| HY-162891 | EGFR-IN-123 | Inhibitor | / | Unkown |
| HY-160828 | O-Desmethyl dacomitinib | Inhibitor | / | Unkown |
| HY-152019 | EGFR/C797S-IN-1 | Inhibitor | / | Unkown |
| HY-178311 | EGFR Ligand-Linker Conjugates 4 | Ligand | / | Unkown |
| HY-163371 | EGFR WT/T790M-IN-1 | Inhibitor | / | Unkown |
| HY-178313 | EGFR ligand-18 | Degrader | / | Unkown |
| HY-168514 | SOS1/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-184720 | VEGFR-2-IN-89 | Inhibitor | / | Unkown |
| HY-158016 | Antiproliferative agent-49 | Inhibitor | / | Unkown |
| HY-158969 | EGFR-IN-113 | Inhibitor | / | Unkown |
| HY-172961 | EGFR-IN-162 | Inhibitor | / | Unkown |
| HY-181142 | Antitumor agent-213 | / | Unkown | |
| HY-147797 | EGFR/HER2/CDK9-IN-2 | Inhibitor | / | Unkown |
| HY-189877 | EGFR-IN-221 | Inhibitor | / | Unkown |
| HY-15990 | CH5164840 | Inhibitor | / | Unkown |
| HY-175608 | EGFR-IN-171 | Inhibitor | / | Unkown |
| HY-158176 | EGFR T790M/L858R-IN-5 | Inhibitor | / | Unkown |
| HY-147741 | DPPY | Inhibitor | / | Unkown |
| HY-157166 | EGFR kinase inhibitor 2 | Inhibitor | / | Unkown |
| HY-183373 | EGFR/PARP-1-IN-1 | Inhibitor | / | Unkown |
| HY-161269 | EGFR-IN-101 | Inhibitor | / | Unkown |
| HY-163860 | EGFR-TK-IN-3 | Inhibitor | / | Unkown |
| HY-101959 | Tyrphostin AG213 | Inhibitor | / | Unkown |
| HY-120412 | SKLB188 | Inhibitor | / | Unkown |
| HY-157399 | EGFR/HER2-IN-10 | Inhibitor | / | Unkown |
| HY-18213 | EGFR-IN-9 | Inhibitor | 98.69% | Unkown |
| HY-P1085 | Epidermal Growth Factor Receptor Peptide (985-996) | Chemical | / | Unkown |
| HY-146154 | EGFR-IN-58 | Inhibitor | / | Unkown |
| HY-174414 | EGFR/HER2-IN-18 | Inhibitor | / | Unkown |
| HY-P10793 | Cyclic(YCDGFYACYMDV) | Inhibitor | / | Unkown |
| HY-180966 | Gly-PEG3-BA | Degrader | / | Unkown |
| HY-182073 | EGFR-IN-207 | Inhibitor | / | Unkown |
| HY-144676 | pan-HER-IN-1 | Inhibitor | / | Unkown |
| HY-162788 | EGFR-IN-121 | Inhibitor | / | Unkown |
| HY-175009 | MRC-G-001 | Inhibitor | / | Unkown |
| HY-RS04474 | Erbb4 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-190486 | ALK/EGFR-IN-4 | Inhibitor | / | Unkown |
| HY-P5745A | TYVPANASL TFA | / | Unkown | |
| HY-P11590 | WGYRGFYC | Ligand | / | Unkown |
| HY-189399 | EGFR/DNA gyrase B Ligand 1 | / | Unkown | |
| HY-153744 | JGK-068S | Inhibitor | / | Unkown |
| HY-187191 | Autophagy-IN/Ferroptosis inducer-modulator-1 | Inhibitor | / | Unkown |
| HY-155969 | EGFR-IN-83 | Inhibitor | / | Unkown |
| HY-175292 | EGFR WT/T790M-IN-3 | Inhibitor | / | Unkown |
| HY-153856A | TAS2940 fumarate | Inhibitor | / | Unkown |
| HY-180917 | PROTAC EGFR degrader 17 | Degrader | / | Unkown |
| HY-162482 | EGFR kinase inhibitor 5 | Inhibitor | / | Unkown |
| HY-155118 | EGFR-IN-81 | Inhibitor | / | Unkown |
| HY-156639 | EGFR/ErbB-2 inhibitor-1 | Inhibitor | / | Unkown |
| HY-158178 | EGFR T790M/L858R-IN-7 | Inhibitor | / | Unkown |
| HY-162602 | EGFR-IN-115 | Inhibitor | / | Unkown |
| HY-189683 | EGFR-IN-220 | Inhibitor | / | Unkown |
| HY-50898S2 | Lapatinib-d5 | Inhibitor | / | Unkown |
| HY-142283BS | N-Desmethyl dosimertinib | / | Unkown | |
| HY-175162 | EGFR ligand-20 | Ligand | / | Unkown |
| HY-144049 | EGFR-IN-32 | Inhibitor | / | Unkown |
| HY-162589 | Lw13 | Inhibitor | 98.26% | Unkown |
| HY-157994 | EGFR WT/T790M-IN-2 | Inhibitor | / | Unkown |
| HY-175588 | EGFR-IN-170 | Inhibitor | / | Unkown |
| HY-161603 | EGFR/HER2-IN-14 | Inhibitor | / | Unkown |
| HY-176279 | Hsp90-IN-42 | Inhibitor | / | Unkown |
| HY-181479 | EGFR-IN-196 | Inhibitor | / | Unkown |
| HY-162300 | EGFR kinase inhibitor 4 | Inhibitor | / | Unkown |
| HY-181766 | EGFR/VEGFR2-IN-11 | Inhibitor | / | Unkown |
| HY-116504 | WB-308 | Inhibitor | / | Unkown |
| HY-156116 | EGFR/CDK2-IN-4 | Inhibitor | / | Unkown |
| HY-107450 | PROTAC Her3-binding moiety 2 | Inhibitor | / | Unkown |
| HY-181777 | Mal-Pip-ValCit-PAB-AZ7550 | Inhibitor | / | Unkown |
| HY-121828 | TX-1123 | Inhibitor | / | Unkown |
| HY-161320 | EGFR-IN-105 | Inhibitor | / | Unkown |
| HY-163663 | AZ14133346 | Inhibitor | / | Unkown |
| HY-50896S1 | Erlotinib-13C6 | Inhibitor | / | Unkown |
| HY-147994 | EGFR/HER2-IN-5 | Inhibitor | / | Unkown |
| HY-171443 | Lyso-Monosialoganglioside GM3 | Inhibitor | / | Unkown |
| HY-161145 | EGFR/microtubule-IN-1 | Inhibitor | / | Unkown |
| HY-184497 | PROTAC EGFR degrader 18 | Degrader | / | Unkown |
| HY-149518 | EGFR/BRAFV600E-IN-3 | Inhibitor | / | Unkown |
| HY-144053 | EGFR-IN-36 | Inhibitor | / | Unkown |
| HY-100663 | Gefitinib impurity 2 | 99.56% | Unkown | |
| HY-175864 | EGFR-IN-173 | Inhibitor | / | Unkown |
| HY-156115 | EGFR/CDK2-IN-3 | Inhibitor | / | Unkown |
| HY-142517 | EGFR-IN-25 | Inhibitor | / | Unkown |
| HY-159519 | EGFR/HER2-IN-16 | Inhibitor | / | Unkown |
| HY-153557A | HER2-IN-14 | Inhibitor | / | Unkown |
| HY-182914 | NGI-189 | Inhibitor | 99.29% | Unkown |
| HY-168559 | EGFR-IN-131 | Inhibitor | / | Unkown |
| HY-170438 | EGFR-IN-139 | / | Unkown | |
| HY-169408 | EGFR-IN-137 | Inhibitor | / | Unkown |
| HY-179485 | EGFR/VEGFR2-IN-10 | Inhibitor | / | Unkown |
| HY-175820 | AGW-11 | Inhibitor | / | Unkown |
| HY-144055 | EGFR-IN-38 | Inhibitor | / | Unkown |
| HY-183754 | EGFR-IN-213 | Inhibitor | / | Unkown |
| HY-174231 | EGFR-IN-163 | Inhibitor | / | Unkown |
| HY-144051 | EGFR-IN-34 | Inhibitor | / | Unkown |
| HY-116091 | EGFR-IN-451 | Inhibitor | / | Unkown |
| HY-142519 | EGFR-IN-27 | Inhibitor | / | Unkown |
| HY-162062 | EGFR WT/T790M/L858R-IN-1 | Inhibitor | / | Unkown |
| HY-189846 | ES3-JFTN | Inhibitor | / | Unkown |
| HY-189464 | EGFR/Akt/STAT3-IN-1 | Inhibitor | / | Unkown |
| HY-172160 | HER2-IN-21 | Inhibitor | / | Unkown |
| HY-184274 | EGFR/c-SRC-IN-1 | Inhibitor | / | Unkown |
| HY-158154 | EGFR-IN-110 | Inhibitor | / | Unkown |
| HY-RS04473 | Erbb4 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-149846 | SIQ17 | Inhibitor | / | Unkown |
| HY-32721S | Neratinib-d6 | Inhibitor | 97.04% | Unkown |
| HY-163722 | EGFR/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-178005 | EGFR-IN-174 | Inhibitor | / | Unkown |
| HY-163632 | EGFR-IN-112 | Inhibitor | / | Unkown |
| HY-178283 | EGFR-IN-177 | Inhibitor | / | Unkown |
| HY-116138 | RG-14467 | Inhibitor | / | Unkown |
| HY-151158 | EGFR/HER2-IN-7 | Inhibitor | / | Unkown |
| HY-143323 | HER2-IN-9 | Inhibitor | / | Unkown |
| HY-172156 | EGFR-TK-IN-5 | Inhibitor | / | Unkown |
| HY-173118 | EGFR-IN-152 | Inhibitor | / | Unkown |
| HY-168623 | EGFR-IN-134 | Inhibitor | / | Unkown |
| HY-145823 | EGFR-IN-42 | Inhibitor | / | Unkown |
| HY-161785 | EGFR-IN-117 | Inhibitor | / | Unkown |
| HY-P11484 | Myosin Regulatory Light Chain MRCL3 (11-24) | / | Unkown | |
| HY-134470 | PP144 | Inhibitor | / | Unkown |
| HY-175173 | EGFR-IN-166 | Inhibitor | / | Unkown |
| HY-151156 | EGFR/HER2-IN-6 | Inhibitor | / | Unkown |
| HY-181115 | EGFR-IN-193 | Inhibitor | / | Unkown |
| HY-185460 | Pertuzumab-LD3 | Inhibitor | / | Unkown |
| HY-RS04471 | Erbb3 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-141486A | PROTAC PARP/EGFR ligand 1 | / | Unkown | |
| HY-181061 | COX/5-LO-IN-2 | Inhibitor | / | Unkown |
| HY-161731 | DS08701581 | Inhibitor | / | Unkown |
| HY-112823S | Almonertinib-d6 | Inhibitor | / | Unkown |
| HY-189361 | EGFR ligand-19 | Ligand | / | Unkown |
| HY-113549 | Erbstatin | Inhibitor | / | Unkown |
| HY-161319 | EGFR-IN-104 | Inhibitor | / | Unkown |
| HY-168469 | EGFR-IN-148 | Inhibitor | / | Unkown |
| HY-P12120 | ErbB-2-binding peptide-2 | Ligand | / | Unkown |
| HY-RS04210 | Egfr Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-158313 | PROTAC EGFR degrader 13 | Inhibitor | / | Unkown |
| HY-185276 | EGFR-IN-204 | Inhibitor | 98.57% | Unkown |
| HY-N3634 | Corylifol C | / | Unkown | |
| HY-175531 | EGFR-IN-169 | Inhibitor | / | Unkown |
| HY-179148 | EGFR-IN-184 | Inhibitor | / | Unkown |
| HY-181829 | Ctx-L3 | Degrader | / | Unkown |
| HY-19730A | Olmutinib hydrochloride | Inhibitor | / | Unkown |
| HY-RS04211 | Egfr Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-151981 | EGFR-IN-74 | Inhibitor | / | Unkown |
| HY-144444 | NSC381467 | Inhibitor | / | Unkown |
| HY-177379 | EGFR ligand-14 | / | Unkown | |
| HY-172091 | CZY43 | Degrader | / | Unkown |
| HY-176556 | EGFR-IN-167 | Inhibitor | / | Unkown |
| HY-147967 | EGFR-IN-63 | Inhibitor | / | Unkown |
| HY-169568 | EGFR-IN-147 | Inhibitor | / | Unkown |
| HY-173146 | EGFR-IN-153 | Inhibitor | / | Unkown |
| HY-155074 | EGFR-IN-79 | Inhibitor | / | Unkown |
| HY-185227 | EphB4-IN-1 | Inhibitor | / | Unkown |
| HY-172111 | EGFR-IN-144 | Inhibitor | / | Unkown |
| HY-147826 | EGFR-IN-60 | Inhibitor | / | Unkown |
| HY-168073 | EGFR/VEGFR2-IN-1 | Inhibitor | / | Unkown |
| HY-179039 | EGFR-IN-183 | Inhibitor | / | Unkown |
| HY-165394 | Melafolone | Inhibitor | / | Unkown |
| HY-P10648 | Herceptide | / | Unkown | |
| HY-178116 | HER2-IN-23 | Inhibitor | / | Unkown |
| HY-172621 | EGFR-IN-159 | Inhibitor | / | Unkown |
| HY-P12278 | NP1 peptide | Inhibitor | / | Unkown |
| HY-164503 | Neptinib | Inhibitor | / | Unkown |
| HY-146325 | HSP90-IN-11 | Degrader | / | Unkown |
| HY-177989 | ER121 | Inhibitor | 98.52% | Unkown |
| HY-169427 | FRF-06-057 | Inhibitor | / | Unkown |
| HY-P992588 | SAR443216 | / | Unkown | |
| HY-161866 | EGFR-IN-118 | Inhibitor | / | Unkown |
| HY-133453 | PROTAC EGFR degrader 1 | Degrader | / | Unkown |
| HY-138298B | Trastuzumab deruxtecan (DAR2) | Inhibitor | / | Unkown |
| HY-149695 | EGFR-IN-91 | Inhibitor | / | Unkown |
| HY-144605 | PROTAC EGFR degrader 3 | Inhibitor | 97.39% | Unkown |
| HY-168655 | EGFR/VEGFR2-IN-3 | Inhibitor | / | Unkown |
| HY-179049 | EGFR/tubulin-IN-1 | Inhibitor | / | Unkown |
| HY-142678 | EGFR-IN-21 | Inhibitor | / | Unkown |
| HY-178353 | EGFR/Cytokine-IN-1 | Inhibitor | / | Unkown |
| HY-100064S1 | O-Desmethyl gefitinib-d6 | Inhibitor | / | Unkown |
| HY-162148 | HNPMI | Inhibitor | 99.57% | Unkown |
| HY-184719 | VEGFR-2-IN-88 | Inhibitor | / | Unkown |
| HY-173500 | MG-3C | Inhibitor | / | Unkown |
| HY-168876 | AZ14240475 | Inhibitor | / | Unkown |
| HY-189360 | PROTAC EGFR degrader 19 | Degrader | / | Unkown |
| HY-114253 | ODS-2004436 | / | Unkown | |
| HY-162099 | VEGFR-IN-4 | Inhibitor | / | Unkown |
| HY-143246 | EGFR kinase inhibitor 1 | Inhibitor | / | Unkown |
| HY-162623 | EGFR/HER2-IN-15 | Inhibitor | / | Unkown |
| HY-RS04467 | Erbb2 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-145844 | EGFR-IN-44 | Inhibitor | / | Unkown |
| HY-150908 | Brigatinib A | Ligand | / | Unkown |
| HY-123891 | NS-062 | Inhibitor | / | Unkown |
| HY-151573 | EGFR/CDK2-IN-1 | Inhibitor | / | Unkown |
| HY-146423 | PROTAC EGFR degrader 6 | Degrader | / | Unkown |
| HY-173218 | anti-NSCLC agent-1 | Inhibitor | / | Unkown |
| HY-100636 | Gefitinib N-oxide | Inhibitor | / | Unkown |
| HY-168112 | EGFR-IN-127 | Inhibitor | / | Unkown |
| HY-181659 | EGFR-IN-201 | Inhibitor | / | Unkown |
| HY-RS04469 | ERBB3 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-181056 | EGFR/COX-2-IN-3 | Inhibitor | 99.76% | Unkown |
| HY-P11890 | GPVGPS | Modulator | / | Unkown |
| HY-144056 | EGFR-IN-39 | Inhibitor | / | Unkown |
| HY-P0221S | PACAP (1-38), human, ovine, rat-13C5,15N TFA | Inducer | / | Unkown |
| HY-159101 | EP26 | Inhibitor | / | Unkown |
| HY-180154 | EGFR/BRAFV600E-IN-6 | Inhibitor | / | Unkown |
| HY-179140 | EGFR/VEGFR2-IN-8 | Inhibitor | / | Unkown |
| HY-157912 | EGFR-IN-102 | Inhibitor | / | Unkown |
| HY-188268 | TXX-1-10 | Inhibitor | / | Unkown |
| HY-183090 | EGFR/VEGFR2-IN-13 | Inhibitor | / | Unkown |
| HY-170543 | Dual Galectin-3/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-176938 | AfaPhos1 | Inhibitor | / | Unkown |
| HY-168427 | Avitinib maleate dihydrate | Inhibitor | / | Unkown |
| HY-158018 | EGFR-TK-IN-2 | Inhibitor | / | Unkown |
| HY-178057 | EGFR-IN-176 | Inhibitor | / | Unkown |
| HY-P11757 | Cyclo[K(N3)larllt] | Ligand | / | Unkown |
| HY-174415 | ZSH-2117 | Degrader | / | Unkown |
| HY-13524A | AG-1478 hydrochloride | Inhibitor | / | Unkown |
| HY-149556 | MTX-241F | Inhibitor | / | Unkown |
| HY-182817 | Len-604 | Inhibitor | / | Unkown |
| HY-181097 | EGFR-IN-192 | Inhibitor | / | Unkown |
| HY-163000 | EGFR-IN-129 | Inhibitor | / | Unkown |
| HY-189142 | EGFR-IN-217 | Inhibitor | / | Unkown |
| HY-144794 | EGFR-IN-46 | Inhibitor | / | Unkown |
| HY-179150 | EGFR-TK-IN-6 | Inhibitor | / | Unkown |
| HY-139884 | EGFR-IN-18 | Inhibitor | / | Unkown |
| HY-145867 | EGFR-IN-45 | Inhibitor | / | Unkown |
| HY-P10792A | HYNIC-H6F | Ligand | / | Unkown |
| HY-172795 | EGFR-IN-158 | Inhibitor | / | Unkown |
| HY-117852 | CGP-59326 | Inhibitor | / | Unkown |
| HY-144760 | EGFR-IN-3 | Inducer | / | Unkown |
| HY-167948 | Dacomitinib metabolite M1/2 | Inhibitor | / | Unkown |
| HY-178242 | PROTAC EGFR degrader 16 | Degrader | / | Unkown |
| HY-W777297 | Lapatinib-13C2,15N Ditosylate | / | Unkown | |
| HY-170932 | EGFR/COX-2-IN-1 | Inhibitor | / | Unkown |
| HY-187692 | IRAK4-IN-35 | Inhibitor | / | Unkown |
| HY-187334 | EGFR-IN-216 | Inhibitor | / | Unkown |
| HY-P11781 | HW12 | Control | / | Unkown |
| HY-158153 | EGFR-IN-108 | Inhibitor | / | Unkown |
| HY-10261S1 | Afatinib-d4 | Inhibitor | / | Unkown |
| HY-162964 | EGFR-IN-126 | Inhibitor | / | Unkown |
| HY-149344 | Anticancer agent 133 | Inhibitor | / | Unkown |
| HY-173619 | EGFR-IN-160 | Inhibitor | / | Unkown |
| HY-143874 | HER2-IN-7 | Inhibitor | / | Unkown |
| HY-169216 | Multi-target kinase inhibitor 3 | Inhibitor | / | Unkown |
| HY-190903 | YNW-1 | Inhibitor | / | Unkown |
| HY-143729 | EGFR-IN-29 | Inhibitor | / | Unkown |
| HY-50898S1 | Lapatinib-d7 dihydrochloride | Inhibitor | / | Unkown |
| HY-183292 | SH-1092 | Inhibitor | / | Unkown |
| HY-180965 | Pro-PEG3-BA | Degrader | / | Unkown |
| HY-189725 | EGFR/HER2-IN-21 | Inhibitor | / | Unkown |
| HY-147794 | CDK9-IN-41 | Inhibitor | 98.84% | Unkown |
| HY-184116 | A2AR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-208666 | EGFR-IN-215 | Inhibitor | / | Unkown |
| HY-100636A | Gefitinib N-oxide hydrochloride | Inhibitor | / | Unkown |
| HY-50898S3 | Lapatinib-d4-1 | Inhibitor | / | Unkown |
| HY-P11078 | LARLLT | / | Unkown | |
| HY-135216 | Antiproliferative agent-54 | Inhibitor | / | Unkown |
| HY-161146 | EGFR-IN-100 | Inhibitor | / | Unkown |
| HY-180949 | EGFR-IN-189 | Inhibitor | / | Unkown |
| HY-152144 | EGFR-IN-75 | Inhibitor | / | Unkown |
| HY-147798 | EGFR/HER2/CDK9-IN-3 | Inhibitor | / | Unkown |
| HY-118175 | RG 14921 | Inhibitor | / | Unkown |
| HY-163417 | HER2-IN-15 | Inhibitor | / | Unkown |
| HY-144050 | EGFR-IN-33 | Inhibitor | / | Unkown |
| HY-180823 | Topoisomerase II/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-181491 | Tubulin-IN-64 | Inhibitor | / | Unkown |
| HY-116277 | Z118332870 | Inhibitor | / | Unkown |
| HY-153557 | HER2-IN-13 | Inhibitor | / | Unkown |
| HY-137786 | EGFR-IN-16 | Inhibitor | / | Unkown |
| HY-147996 | EGFR-IN-67 | Inhibitor | / | Unkown |
| HY-P9912S | 15N-Labeled Pertuzumab | / | Unkown | |
| HY-177270 | CHNQD-01281 | Modulator | / | Unkown |
| HY-13272S3 | Dacomitinib-d10 | Inhibitor | / | Unkown |
| HY-155178 | Antiproliferative agent-34 | Inhibitor | / | Unkown |
| HY-174841 | EGFR/HER2-IN-19 | Inhibitor | / | Unkown |
| HY-169308 | EGFR-IN-132 | Inhibitor | / | Unkown |
| HY-168170 | EGFR/VEGFR2-IN-2 | Inhibitor | / | Unkown |
| HY-180541 | EGFR-IN-190 | Inhibitor | / | Unkown |
| HY-189465 | EGFR/STAT3-IN-2 | Inhibitor | / | Unkown |
| HY-156470 | Multi-kinase-IN-6 | Inhibitor | / | Unkown |
| HY-18957B | Lifirafenib maleate | Inhibitor | / | Unkown |
| HY-169982 | EGFR-IN-136 | Inhibitor | / | Unkown |
| HY-156991 | NODAGA-NHS | / | Unkown | |
| HY-172469 | DSPE-PEG1000-GE11 | / | Unkown | |
| HY-147860 | EGFR-IN-61 | Inhibitor | / | Unkown |
| HY-163880 | EGFR-IN-119 | Inhibitor | / | Unkown |
| HY-P10994 | Eps8 peptide 327 | Inhibitor | / | Unkown |
| HY-103437 | EGFR-IN-80 | Inhibitor | / | Unkown |
| HY-179599 | Dyrk1A-IN-15 | Inhibitor | / | Unkown |
| HY-149401 | EGFR-IN-82 | Inhibitor | / | Unkown |
| HY-159512 | EGFR kinase inhibitor 7 | Inhibitor | / | Unkown |
| HY-N9684 | Degalactotigonin | Inhibitor | / | Unkown |
| HY-173188 | EGFR-IN-154 | Inhibitor | / | Unkown |
| HY-170661 | EGFR-IN-142 | Inhibitor | / | Unkown |
| HY-176744 | HER2-IN-22 | Inhibitor | / | Unkown |
| HY-158988 | EGFR-IN-114 | Inhibitor | / | Unkown |
| HY-147862 | EGFR-IN-62 | Inhibitor | / | Unkown |
| HY-142680 | EGFR-IN-23 | Inhibitor | / | Unkown |
| HY-173520 | EGFR/HDAC-IN-1 | Inhibitor | / | Unkown |
| HY-155200 | EGFR-IN-84 | Inhibitor | / | Unkown |
| HY-173501 | EGFR-IN-157 | Inhibitor | / | Unkown |
| HY-114535 | Jaceidin | Inhibitor | / | Unkown |
| HY-173367 | Anticancer agent 271 | Inhibitor | / | Unkown |
| HY-157432 | EGFR-IN-97 | Inhibitor | / | Unkown |
| HY-181923 | IMP-Zn | / | Unkown | |
| HY-162323 | EGFR-IN-106 | Inhibitor | / | Unkown |
| HY-W409652 | CLK1/4-IN-2 | Inhibitor | / | Unkown |
| HY-178942 | EGFR/VEGFR2-IN-9 | Inhibitor | / | Unkown |
| HY-163419 | HER2-IN-18 | Inhibitor | / | Unkown |
| HY-178142 | Multi-kinase-IN-7 | Inhibitor | / | Unkown |
| HY-172179 | EGFR/VEGFR2-IN-5 | Inhibitor | / | Unkown |
| HY-146138 | EGFR-IN-57 | Inhibitor | / | Unkown |
| HY-W008914 | (E/Z)-CP-724714 | Inhibitor | / | Unkown |
| HY-162881 | DS06652923 | Inhibitor | / | Unkown |
| HY-138298D | Trastuzumab deruxtecan (DAR6) | Inhibitor | 95.25% | Unkown |
| HY-168433 | LSD1/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-147995 | EGFR-IN-64 | Inhibitor | / | Unkown |
| HY-189291 | EGFR-IN-218 | Inhibitor | / | Unkown |
| HY-147248 | Opadotina | Inhibitor | / | Unkown |
| HY-144097 | HER2-IN-8 | Inhibitor | / | Unkown |
| HY-151161 | EGFR/HER2-IN-8 | Inhibitor | / | Unkown |
| HY-177380 | EGFR ligand-14-PEG3-Boc | / | Unkown | |
| HY-187517 | Anticancer agent 357 | Inhibitor | / | Unkown |
| HY-179143 | EGFR-IN-185 | Inhibitor | / | Unkown |
| HY-W706930 | DCBA-d10 | / | Unkown | |
| HY-157402 | Topoisomerase II/EGFR-IN-1 | / | Unkown | |
| HY-181093 | EGFR-IN-191 | Inhibitor | / | Unkown |
| HY-P2548 | pp60 (v-SRC) Autophosphorylation Site, Phosphorylated | / | Unkown | |
| HY-183788 | EGFR-IN-212 | Inhibitor | / | Unkown |
| HY-178009 | EGFR-IN-175 | Inhibitor | / | Unkown |
| HY-180964 | Lys-PEG3-BA | Degrader | / | Unkown |
| HY-112405 | BPIQ-I | Inhibitor | / | Unkown |
| HY-189734 | EGFR/VEGFR2-IN-14 | Inhibitor | / | Unkown |
| HY-144044 | EGFR-IN-30 | Inhibitor | / | Unkown |
| HY-15772GL | Osimertinib (GMP Like) | Inhibitor | / | Unkown |
| HY-174826 | EGFR-IN-164 | Inhibitor | / | Unkown |
| HY-183123 | EGFR T790M/FAK-IN-1 | Inhibitor | / | Unkown |
| HY-149517 | EGFR/BRAFV600E-IN-2 | Inhibitor | / | Unkown |
| HY-171958 | PROTAC EGFR degrader 12 | Degrader | / | Unkown |
| HY-164413 | CLM3 | Inhibitor | / | Unkown |
| HY-168173 | EGFR-IN-130 | Inhibitor | / | Unkown |
| HY-156097 | Anticancer agent 158 | Inhibitor | / | Unkown |
| HY-155227 | ALK/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-151162 | HER2-IN-12 | Inhibitor | / | Unkown |
| HY-164399 | SST0116CL1 | Degrader | / | Unkown |
| HY-W174279 | Tyrphostin 8 | Inhibitor | 99.10% | Unkown |
| HY-155227S | ALK/EGFR-IN-1-d5 | Inhibitor | / | Unkown |
| HY-156114 | EGFR/CDK2-IN-2 | Inhibitor | / | Unkown |
| HY-103566A | LY456236 free base | Inhibitor | / | Unkown |
| HY-168064 | EGFR-IN-124 | Inhibitor | / | Unkown |
| HY-187533 | EGFR AUTOTAC-1 | Degrader | / | Unkown |
| HY-144054 | EGFR-IN-37 | Inhibitor | / | Unkown |
| HY-153605 | EGFR-IN-77 | Inhibitor | / | Unkown |
| HY-160087 | SG3376 | Ligand | / | Unkown |
| HY-163657 | HER2-IN-20 | Inhibitor | / | Unkown |
| HY-162483 | EGFR kinase inhibitor 6 | Inhibitor | / | Unkown |
| HY-180536 | HB-EGF-IN-1 | Inhibitor | / | Unkown |
| HY-151377 | RET-IN-19 | Inhibitor | / | Unkown |
| HY-103443A | HKI-357 dimaleate | Inhibitor | / | Unkown |
| HY-111072 | ADS103317 | / | Unkown | |
| HY-100742R | GNE-140 racemate (Standard) | Inhibitor | / | Unkown |
| HY-111250 | SYR127063 | Inhibitor | / | Unkown |
| HY-114667 | Lavendustin C6 | Inhibitor | / | Unkown |
| HY-135725 | D-69491 hydrochloride | Inhibitor | / | Unkown |
| HY-164527 | Si306 | Inhibitor | / | Unkown |
| HY-180498 | NSC 57148 | Inhibitor | / | Unkown |
| HY-32718S | Pelitinib-d6 | / | Unkown | |
| HY-110045 | ZM-306416 hydrochloride | Inhibitor | / | Unkown |
| HY-10325R | CL-387785 (Standard) | Inhibitor | / | Unkown |
| HY-183400 | BIM-46174 | Inhibitor | / | Unkown |
| HY-N14636 | Paeciloquinone B | Inhibitor | / | Unkown |
| HY-180480 | NSC 104999 | Ligand | / | Unkown |
| HY-168305 | EGFR ligand-11 | / | Unkown | |
| HY-160068 | 2-2(t) aptamer sodium | Chemical | 99.28% | Unkown |
| HY-158828A | SSO111 sodium scrambled negative control | / | Unkown | |
| HY-19909A | NRC-2694-A | Inhibitor | / | Unkown |
| HY-183402 | FLLL12 | Inhibitor | / | Unkown |
| HY-N20729 | Eucommin A | Modulator | / | Unkown |
| HY-W740378 | 1,2,3,4-Tetrahydro Staurosporin | Inhibitor | / | Unkown |
| HY-169566 | EGFR-IN-146 | Inhibitor | / | Unkown |
| HY-159047 | EGFR ligand-10 | Degrader | / | Unkown |
| HY-158829A | SSOe26 sodium scrambled negative control | / | Unkown | |
| HY-N14637 | Paeciloquinone C | Inhibitor | / | Unkown |
| HY-15495B | (3S)-Tanzisertib hydrochloride | Inhibitor | / | Unkown |
| HY-16069S | Tucatinib-d6 | Inhibitor | / | Unkown |
| HY-15769A | WHI-P180 hydrochloride | Inhibitor | / | Unkown |
| HY-183397 | Avitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-12000R | AG490 (Standard) | Inhibitor | / | Unkown |
| HY-50896S3 | Erlotinib-d8 | Inhibitor | / | Unkown |
| HY-169948 | BML-265 | Inhibitor | / | Unkown |
| HY-14674A | CP-724714 succinate | Inhibitor | / | Unkown |
| HY-N14639 | Paeciloquinone E | Inhibitor | / | Unkown |
| HY-N14635 | Paeciloquinone A | Inhibitor | / | Unkown |
| HY-184315 | LDC8201 | Inhibitor | / | Unkown |
| HY-116068 | DW532 | Inhibitor | / | Unkown |
| HY-111300 | G3130 | Degrader | / | Unkown |
| HY-50896S2 | Erlotinib-d4 | Inhibitor | / | Unkown |
| HY-158828 | SSO111 sodium | / | Unkown | |
| HY-117523 | (Z)-RG-13022 | Inhibitor | / | Unkown |
| HY-118032 | Bozepinib | Inhibitor | / | Unkown |
| HY-135727 | PF-6422899 | Inhibitor | / | Unkown |
| HY-N14638 | Paeciloquinone D | Inhibitor | / | Unkown |
| HY-156487 | CNBDA | Inhibitor | / | Unkown |
| HY-50898S4 | Lapatinib-d7 | Inhibitor | / | Unkown |
| HY-183377 | DMBT | Inhibitor | / | Unkown |
| HY-169755 | Tyrphostin 63 | Inhibitor | / | Unkown |
| HY-180325 | DDC4002 | Inhibitor | / | Unkown |
| HY-124633 | NEU-1953 | Inhibitor | / | Unkown |
| HY-169570 | EGFR-IN-149 | Inhibitor | / | Unkown |
| HY-10263 | BMS-554417 | Activator | / | Unkown |
| HY-190490 | PAK4-IN-8 | Inhibitor | / | Unkown |
| HY-117252 | HS-72 | / | Unkown | |
| HY-158829 | SSOe26 sodium | / | Unkown | |
| HY-178740 | GI261520A | Inhibitor | / | Unkown |
| HY-137081 | AKOS024836912 | Inhibitor | / | Unkown |
| HY-153887 | HyT36(-Cl) | Control | / | Unkown |
| HY-163396 | EGFR-IN-107 | Inhibitor | / | Unkown |
| HY-W259575 | CDKi free base | Inhibitor | / | Unkown |
| HY-183456 | Tyrphostin AG17 | Inhibitor | / | Unkown |
| HY-146262 | LDC0496 | Inhibitor | / | Unkown |
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9907A | Trastuzumab (anti-HER2) | Inhibitor | 99.838% | Unkown |
| HY-P9S0008 | Cetuximab (PBS) | Inhibitor | 99.33% | Unkown |
| HY-P99854 | Disitamab | Inhibitor | 98.73% | Unkown |
| HY-P9912A | Pertuzumab (anti-HER2) | Inhibitor | 99.10% | Unkown |
| HY-P990947 | Tilatamig | Inhibitor | 99.99% | Unkown |
| HY-P99684 | Laprituximab | Inhibitor | 99.74% | Unkown |
| HY-P990238 | Anti-Human/Rat HER2 (neu) Antibody (7.16.4) | Inhibitor | 95.00% | Unkown |
| HY-P9977A | Amivantamab (FUT8-KO) | Inhibitor | 99.00% | Unkown |
| HY-P99892 | Serclutamab | 99.97% | Unkown | |
| HY-P99324 | Tomuzotuximab | Inhibitor | ≥99.0% | Unkown |
| HY-P99715 | Losatuxizumab | Inhibitor | 99.44% | Unkown |
| HY-P99406A | Petosemtamab (FUT8-KO) | Degrader | 99% | Unkown |
| HY-P99558 | Timigutuzumab | Inhibitor | 97.53% | Unkown |
| HY-P990962 | Vislarafusp alfa | 98.98% | Unkown | |
| HY-P99888 | Pimurutamab | 99.42% | Unkown | |
| HY-P990978 | Caxmotabart | 96.56% | Unkown | |
| HY-P990909 | Calotatug | 98% | Unkown | |
| HY-P992137 | Turigrobart | Inhibitor | 99.9% | Unkown |
| HY-P991966 | Anti-Human/Mouse EGFR Antibody (7A7) | 99.45% | Unkown | |
| HY-P991779 | Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) | Inhibitor | 99.05% | Unkown |
| HY-P992107 | Dulpatatug | Inhibitor | 99.09% | Unkown |
| HY-P991505 | Anti-HER3 Antibody (Ab562) | Antagonist | 99.63% | Unkown |
| HY-P991159 | Ruzaltatug | Inhibitor | 95.69% | Unkown |
| HY-P991780 | Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) | Inhibitor | 97.589% | Unkown |
| HY-P990972 | Azerutamig | / | Unkown | |
| HY-P992140 | Varzutamig | Inhibitor | / | Unkown |
| HY-P991980 | H2Mab-139 | Inhibitor | / | Unkown |
| HY-P99295A | Imgatuzumab (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991986 | Anti-Epiregulin Antibody | Inhibitor | / | Unkown |
| HY-P990248 | Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) | Inhibitor | 98.53% | Unkown |
| HY-P991977 | BSI-001 | Inhibitor | / | Unkown |
| HY-P991236 | MHES0488A | Inhibitor | 95.83% | Unkown |
| HY-P991092A | IBI-334 (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991784 | Anti-Mouse/Human EGFR (domain III) Antibody (EMab-88) | Inhibitor | / | Unkown |
| HY-P992171 | ADCT-701 Antibody | / | Unkown | |
| HY-P991967 | AVID100 Antibody | Inhibitor | / | Unkown |
| HY-P991985 | Anti-Her4 Antibody | Inhibitor | / | Unkown |
| HY-P991979 | Erbicin | Inhibitor | / | Unkown |
| HY-P991239 | NM-02 | Inhibitor | / | Unkown |
| HY-P991241 | Anti-ERBB3/HER3 (29Z6) | Inhibitor | / | Unkown |
| HY-P991234 | COVA208 | Degrader | / | Unkown |
| HY-P992401 | M802 | Inhibitor | / | Unkown |
| HY-P991970 | REGN3124 | Inhibitor | / | Unkown |
| HY-P991783 | Anti-Mouse EGFR (domain I) Antibody (EMab-300) | Inhibitor | / | Unkown |
| HY-P990755A | Pamvatamig (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P990408 | Anti-ERBB1/EGFR/HER1 Antibody | Inhibitor | / | Unkown |
| HY-P991245 | Anti-ERBB3/HER3 (SGP1) | Inhibitor | / | Unkown |
| HY-P991969 | LR004 | Inhibitor | / | Unkown |
| HY-P991243 | MP-RM-1 | Inhibitor | 96.29% | Unkown |
| HY-P9968A | Nimotuzumab (powder) | Inhibitor | / | Unkown |
| HY-P991573 | Anti-EGFR Antibody (D2C7) | Inhibitor | / | Unkown |
| HY-P991968 | HTI-1511 Antibody | Inhibitor | / | Unkown |